

INDEX

Volume Thirteen — January through December 1979

DRUG INTELLIGENCE AND CLINICAL PHARMACY

JANUARY	Pages 1 - 64	JULY/AUGUST	Pages 377 - 480
FEBRUARY	Pages 65 - 128	SEPTEMBER	Pages 481 - 560
MARCH	Pages 129 - 184	OCTOBER	Pages 561 - 640
APRIL	Pages 185 - 248	NOVEMBER	Pages 641 - 720
MAY	Pages 249 - 312	DECEMBER	Pages 721 - 816
JUNE	Pages 313 - 376		

A

Abstracting, list of systems, 513
Acetaminophen, disposition in treated epileptics (ab) 549
Acetazolamide, treatment of periodic hypokalemic paralysis, 325
Acetylcysteine, kinetics in respiratory disorders (ab) 59; in rheumatology (CTF) 789; in urology (CTF) 440
Acetylsalicylic acid see **Aspirin**
Acne, treatment with 13-cis-retinoic acid (ab) 552
Activated Charcoal see **Charcoal**
Adenine Arabinoside see **Vidarabine**
Adenosine, inhibitor of platelet aggregation, 80
Adverse Drug Reactions, adenine arabinoside, SIADH (ab) 293; alcohol, cancer of the oropharynx (CTF) 625; allopurinol, hypersensitivity reaction, 218; ammonium chloride, encephalopathy (CTF) 440; amphetamine abuse, rhabdomyolysis (DIAS Rounds) 161; amphotericin B, toxic delirium (CTF) 541; antipsychotic drugs, blood dyscrasia, 201; antipsychotic drugs, cardiovascular effects, 200; antipsychotic drugs, epileptic seizures, 203; antipsychotic drugs, extrapyramidal reactions, 203; antipsychotic drugs, galactorrhea and amenorrhea, 200; antipsychotic drugs, hypotension, 199; antipsychotic drugs, jaundice, 201; antipsychotic drugs, tardive dyskinesia, 206; antipsychotic drugs, thermoregulation, 200; antipsychotic drugs, withdrawal reactions, 203; ascorbic acid, high-dose therapy (CTF) 625; aspirin, hepatitis (ab) 541; azatadine, psychomotor functions (CTF) 440; captopril, nephrotic syndrome (CTF) 707; carbamazepine, dystonia (CTF) 440; cephaloridine, colitis (CTF) 707; chemotherapy, gonadal dysfunction (ab) 119; chemotherapy, gynecomastia (ab) 119; chenodeoxycholic acid, indirect bilirubin increases (CTF) 541; chlorambucil, myelofibrosis (CTF) 707; chloroquine, retinopathy (CTF) 707; chlorpromazine, extended therapy (CTF) 625; chlorpromazine, phototoxicity (CTF) 789; cimetidine, gastric carcinoma (CTF) 440; cimetidine, hepatitis (CTF) 541; cimetidine, impotence (ab) 293; cimetidine, sexual dysfunction (ab) 455; cimetidine, thrombocytopenia (CTF) 707; cisplatin, hypomagnesemia (CTF) 541; clindamycin, anaphylaxis (case reports) 348; clofibrate, acute myocardial syndrome (ab) 454; clofibrate, gallstones (ab) 118; clomipramine citrate, ovarian cyst (CTF) 789; clonidine, overdose, 778; cost to society, 421; criteria for classification, 269; cyclobenzaprine, assessment of reactions (CTF) 440; cyclophosphamide, anaphylaxis (CTF) 440; deficiency of drug information, 86; detected by a computer drug-drug interaction program, 774; diazepam, gynecomastia (CTF) 541; diethylstilbestrol, cervical carcinoma (CTF) 707; diethylstilbestrol, peliosis (CTF) 440; disopyramide, agranulocytosis (letter) 165; disopyramide, seizure and possible MI (CTF) 789; disulfiram, hepatotoxicity (CTF) 625; ergotamine, angina and ventricular fibrillation (CTF) 707; erythromycin ethyl succinate, hepatotoxicity, (letter), 238; estrogen, endometrial cancer (ab) 293; ethchlorvynol, iv, pulmonary edema, 96; fludrocortisone, hypertension (CTF) 541; fluorocytosine, bone marrow toxicity, 72; furosemide, cirrhosis (ab) 544; gentamicin, thrombocytopenia (letter) 238; gold, intrahepatic cholestasis (CTF) 789; heparin, thrombocytopenia (CTF) 440, 789; heroin, thrombocytopenia purpura (CTF) 541; hydralazine, sudden withdrawal (CTF) 625; ibuprofen, hemolytic anemia (CTF) 541; immunization, active and passive, 389; incidence 421; influenza vaccine, Guillain-Barre Syndrome (CTF) 789; isoniazid, fever (ab) 358; insulin, allergic reaction (CTF) 440; lithium intoxication, 494; lithium, neurotoxicity (CTF) 789; magnesium sulfate, pulmonary edema (CTF) 625; mannitol, hyperosmolarity (CTF) 707; methadone, edema and

weight gain (CTF) 625; methotrexate, anaphylactic reaction (CTF) 707; methoxsalen photochemotherapy, cutaneous carcinoma (ab) 455; metronidazole, cancer risk (CTF) 707; miconazole, hyperlipidemia (CTF) 789; molindone, galactorrhea (CTF) 625; nafcillin, hypokalemia (CTF) 625; neuroleptics, urinary incontinence (CTF) 625; nitrofurantoin, chronic liver disease (CTF) 707; nitrofurantoin, hepatitis (CTF) 625; nitroprusside, hypertension (CTF) 707; organic solvents, CNS defects (CTF) 707; oxacillin, hepatitis (CTF) 440; paracetamol, chronic hepatic inflammation (ab) 359; paracetamol, fibrosis (ab) 359; penicillamine, hepatitis (CTF) 440; penicillamine, myasthenia gravis (CTF) 789; phenelzine, angiosarcoma (CTF) 625; phenylpropanolamine, nephritis (CTF) 625; prazosin, ANA increase (CTF) 707; primidone, familial embryopathy (CTF) 440; propranolol, sexual dysfunction (CTF) 625; reporting method, 781; spironolactone, gynecomastia (ab) 118; sulindac, overdose, 736; tamoxifen, hypercalcemia (CTF) 789; timolol, bronchial asthma (CTF) 707; tobramycin, loss of vestibular function (CTF) 789; tobramycin, thrombocytopenia (letter) 238; Tums[®], hypercalcemia (case report) 350; valproic acid, hepatic failure (CTF) 440; valproic acid, hepatotoxicity (CTF) 789; valproic acid, Reyes-like syndrome (ab) 541; vasopressin, gastric necrosis (CTF) 541; vitamin E, thrombophlebitis (CTF) 440
Adverse Reactions see also **Adverse Drug Reactions**; (CTF) alcohol, cancer of the oropharynx, 625; ammonium chloride, encephalopathy, 440; ascorbic acid, high-dose therapy, 625; azatadine, psychomotor functions, 440; captopril, nephrotic syndrome, 707; carbamazepine, dystonia and opisthotonus, 440; cephaloridine, colitis, 707; chlorambucil, myelofibrosis, 707; chloroquine, retinopathy, 707; chlorpromazine, extended therapy, 625; chlorpromazine, phototoxicity, 789; cimetidine, gastric carcinoma, 440; cimetidine, thrombocytopenia, 707; clomipramine citrate, ovarian cyst, 789; cyclobenzaprine, assessment of reactions, 440; cyclophosphamide, anaphylactic reaction, 440; diethylstilbestrol, cervical carcinoma, 707; diethylstilbestrol, peliosis, 440; disopyramide, seizure and possible MI, 789; disulfiram, hepatotoxicity, 625; ergotamine, angina and ventricular fibrillation, 707; gold, intrahepatic cholestasis, 789; heparin, thrombocytopenia, 440, 789; hydralazine, sudden withdrawal, 625; influenza vaccine, Guillain-Barre Syndrome, 789; insulin, allergic reaction, 440; lithium, neurotoxicity, 789; magnesium sulfate, pulmonary edema, 625; mannitol, hyperosmolarity, 707; methadone, edema and weight gain, 625; methotrexate, anaphylactic reaction, 707; metronidazole, cancer risk, 707; miconazole, hyperlipidemia, 789; molindone, galactorrhea, 625; nafcillin, hypokalemia, 625; neuroleptics, urinary incontinence, 625; nitrofurantoin, chronic liver disease, 707; nitrofurantoin, hepatitis, 625; nitroprusside, hypertension, 707; organic solvents, CNS defects, 707; oxacillin, anicteric hepatitis, 440; penicillamine, cholestatic hepatitis, 440; penicillamine, myasthenia gravis, 789; phenelzine, angiosarcoma, 625; phenylpropanolamine, nephritis, 625; prazosin, ANA increase, 707; primidone, familial embryopathy, 440; propranolol, sexual dysfunction, 625; tamoxifen, hypercalcemia, 789; timolol, bronchial asthma, 707; tobramycin, loss of vestibular function, 789; valproic acid, hepatic failure, 440; valproic acid, thrombocytopenia, 440; valproic acid, hepatotoxicity, 789; vitamin E, thrombophlebitis, 440
Akathisia, antipsychotic drugs, 205
Albumin, influence of drugs on bilirubin binding, 498; in intravenous therapy (CTF) 439; in neurology (CTF) 624

Alcohol, Surgeon General's advisory, 637
Alexander, Michael R. (coauthor) see **Guernsey, Brock G.**, 430
Allergic Rhinitis, use of hydroxyzine (ab) 549
Allopurinol, hypersensitivity reactions, 219; indirect hypersensitivity reaction (case study) 218; in urology (CTF) 789
Alpha-MPT, and pheochromocytoma, (DIAS Rounds) 597
Alprenolol, after myocardial infarction (ab) 57
Amantadine, in toxicology (CTF) 541
Amenorrhea, antipsychotic drugs, 200
American Association of Colleges of Pharmacy, announcement of 1980 International Congress, 799
American College of Clinical Pharmacy, founded, 564, (ed) 608; meeting, 564; officers, 564
American Nurses' Association, cooperation with the U.S. Pharmacopeial Convention, 373
American Society of Consultant Pharmacists, bylaws, revision, 554; Lilly Survey, report, 554; news, 717
American Society of Hospital Pharmacists, Donald E. Franke, founder and contributor (ed) 164
Amikacin, faulty assessment of microbe resistance with disc-sensitivity testing (case report) 537
Aminoglycosides see also **Individual Drug Names**, dosing adjustments (letter) 44; interaction with piperacillin, ticarcillin, and carbenicillin (ab) 119
Aminophylline, in gastroenterology (CTF) 539
Amiodarone, in ventricular arrhythmia (case study) 397
Amitriptyline, compared with L-tryptophan, 392; in psychiatry, 706
Amobarbital, in psychiatry (CTF) 540
Amoxicillin, in infectious disease (CTF) 788; pharmacokinetics and dosing in changing renal function (ab) 362
Amphotericin B, compared with fluorocytosine, 72; ointment, for oral candidiasis, 489; in oncology (CTF) 624
Ampicillin, compared to cacyllin (ab) 359; in infectious disease (CTF) 540; utilization with clindamycin (case report) 349
Amritone, hemodynamic assessment (ab) 294
Ankyroscopic Lateral Sclerosis, modified neurotoxin (MNT) 558
Analgesics, in gastroenterology (CTF) 623
Anderson, John T., (author) letter, tobramycin, gentamicin and thrombocytopenia, 238
Anderson, Philip O. (coauthor) see **Freeman, Debra**, 261
Androgens, in hematology (CTF) 623
Anesthesiology (CTF) cimetidine, 787; dantrolene sodium, 705; dopamine, 438; droperidol, 787; etomidate, 539; fentanyl, coronary artery disease patients, 438; lithium, 539; milk of magnesia, obstetrics, 539
Anesthetics, in anesthesiology (CTF) 623; topical, for intracranial aphthous, 490
Angina Pectoris, β -blocking agents, 550
Angiography, use of intraarterial lidocaine (DIAS Rounds) 596
Antacid, effects on diazepam (ab) 172
Antibiotics, in oncology (CTF) 706; prophylactically in infectious disease (CTF) 705
Anticholinergic Agents, counteracting adverse reactions to antipsychotic drugs, 205
Antidepressant Drugs see **Individual Drug Names**
Antidiarrheal Agents, in gastroenterology (CTF) 539
Antihypertensive Agents see **Hypertensive Agents**
Antineoplastic Agents see **Chemotherapy**; **Individual Drug Names**
Antipalelet drugs, inadvertent use (letter) 451; mechanisms and usage (letter) 451
Anxiety, drug treatment (ab) 456
Aphthous, intraoral, treatment protocol, 490
Apnea, clonidine overdose, 778; of prematurity (case study) 24; theophylline, treatment with, 27; treatment with oxtriphylline in newborns (letter) 238
Archambault, George F. (coauthor) see **Dodds, Arthur W.**, 290; (ed) **Clinical Pharmacist or Clinical Phar-**

macologist? 310; (ed) GMP, GDP, and Unit-of-Use — An Update, 802; (ed) Infection Control in Hospitals — What Role Does Pharmacy Play? 638; (ed) Metratricion, 376; (ed) The KI "Solution," 478; (ed) They'll Come Marching In . . . 560; (ed) Unit Dose System Can Prevent Medication Errors — Only If Monitored Properly, 720; (ed) Why at 70? Because!, 232; (editor) Washington News and Comments, 307, 373, 473, 554, 635, 717, 799

Arterial Disease, and antiplatelet drugs, 81

Ascorbic Acid, effect with L-tryptophan, 393; ineffective in nephropathic cystinosis (ab) 550; in oncology (CTF) 788

Aspirin, as antiplatelet agent, 78; bioavailability (ab) 173; compared with nifedipine (ab) 174; compared to sulindac, 736; contraindications in primary hemostatic disorders (letter) 453; determination of area under the curve by constant blood withdrawal method, 411; in cardiovascular disease (CTF) 705; in gastroenterology (CTF) 438; in hematology (CTF) 540; in rheumatology (CTF) 789; in threatened TIA (ab) 56; mechanism for inhibition of platelet aggregation (letter) 451

Asthma, and analgesics, 676; beclomethasone (ab) 55; beclomethasone dipropionate aerosol, patient consultation, 767; cinnatizine (ab) 458; salbutamol (ab) 58; theophylline use (ab) 173

Atenolol, in cardiovascular disease (CTF) 623

Atropine Sulfate, in pulmonary disease (CTF) 541

Atrolin, pharmacokinetics (ab) 121

Asulidine, in pediatrics (CTF) 439

B

Baars, Ronald E. (coauthor) authors' reply, see Rapp, Robert P., 47; (coauthor) authors' response, see Rapp, Robert P., 168

Bacampicillin, in infectious disease (CTF) 788

Ballentine, Ron (author) book review, 301

"Barefoot Doctor," in Chinese medicine, 470

Barreuther, Alan (author) letter, paraquat contaminated marijuana, 43

Bartiluc, Andrew J. (coauthor) letter, why not more pharmacists' authors' reply, 298

Bartley, Robert L. (author) letter, news not fit to print, 110

Bas, Peter (coauthor) letter, see Eaton, Margaret, 699

Beasley, John W. (coauthor) The Clinical Community Pharmacist — a proposal, 351

Beck, Diane E. (coauthor) An Evaluation of Dosing Regimens for Insulin in Diabetic Ketocidosis, 572

Beckner, R. Randolph (author) Valproic Acid Evaluation, 18

Beclomethasone Dipropionate aerosol, patient consultation recommendations, 767; asthma (ab), 58

Bellward, Gail D. (coauthor) see Warren, Betty L., 680, 741

Bendectin[®], teratogenicity, 800

Bendroflumethiazide, in urology (CTF) 541

Benzodiazepines see also Individual Drug Names, decreased plasma clearance with disulfiram (ab) 119; in general medicine (CTF) 438; use in glaucoma (letter) 109

Bergman, H. David (author) Cefamandole Evaluation, 144

Berlow, Leonard (author) letter, comment on drug compilation, 526

Bernstein, Linda R. (coauthor) (DIAS Rounds), dantrolene sodium and malignant hyperthermia syndrome, 40

Beta-Adrenergic Blocking Agents, in cardiovascular disease (CTF) 438, 539; in ophthalmology (CTF) 540

Beta-Blockers, drugs, coronary disease (ab) 57

Betamethasone, compared to desamethasone for prevention of respiratory distress syndrome (letter) 526; in obstetrics/gynecology (CTF) 624; prevention of respiratory distress syndrome (DIAS Rounds) 526

Bilirubin, influence of drugs on binding to albumin, 498

Bioavailability see Biopharmaceutics

Biopharmaceutics, bioavailability of aspirin (ab) 173; L-tryptophan, 391; oxprenolol (ab) 457; prazosin, 213

Bleeding, with continuous heparin infusion (case report) 609

Blood Dyscrasias, antipsychotic drugs, 201

Bond, C.A. (author) book review, 366, 531

Books Received, Advances in Epileptology 1977 (H. Meinardi and A.J. Rowan), 302; The American Biomedical Network — Health Care Systems in America: Present and Future (S.B. Day, R.V. Cudihy and H.H. Fudenberg), 366; Annual Reports in Medicinal Chemistry, (Frank H. Clarke), 366; The Chemistry of the Tetracycline Antibiotics (Lester A. Mitscher), 366; Drug Abuse: Modern Trends, Issues, and Perspectives (Arnold Schecter, Harold Alksne, and Edward Kaufman), 302; Drug Fate & Metabolism: Methods and Techniques, Volume 2 (Edward R. Garrett and Jean L. Hirtz), 302; Drug Metabolism in Man (J.W. Gorrod and A.H. Beckett), 366; Epidemiological Evaluation of Drugs (Colombo, Shapiro, Slone and Tognoni), 302; The Future of the Multinational Pharmaceutical Industry to 1990 (Barrie G. James), 366; The Life/Death Ratio — Benefits and Risks in Modern Medicine (Walter S. Ross), 302

Books Reviewed, Alder Hey Book of Children's Doses (S.C. Anderson, R.J. Brereton, D.C. Davidson, R.E. Pugh, and C.S. Smith) 615; Cardiovascular Drugs, Volume 1. Cardiovascular Drugs, Volume II. (Craze S. Avery) 364; Chemotherapy of Infection (William B. Pratt) 59; Clinical Pharmacokinetics: Proceedings of an International Symposium at Salzburger-Ringelheim (W.A. Ritschel) 51; Clinical

Pharmacology (P. Turner and A. Richens) 784; Contemporary Standards for Pharmacotherapy of Mental Disorders (Jerome Levine) 531; Death By Prescription (William A. Siler, Michael R. Sawdey, and Barbara C. Meisner) 52; De Haen Non-proprietary Name Index, Volume X (Paul de Haen) 53; Disposition of Toxic Drugs and Chemicals in Man — Volume I: Centrally Acting Drugs (Randall C. Baselt) 170; Drug Addiction I, Drug Addiction II (William R. Martin) 117; Drugs and the Elderly, Revised 1978 (Ronald C. Kayne) 365; Drugs: How They Act and Why (Alex Gringauz) 301; Drug Toxicity (J.W. Corrod) 614; Endocrine Disease: Practical Diagnosis (Stanley G. Korenman, Daryl K. Granner, and Barry M. Sherman) 532; Enzymes in Anesthesiology (F. F. Foldes) 170; Facts and Comparisons (Erwin K. Kastrup and James R. Boyd) 533; Gaddum's Pharmacology, Eighth Edition (A.S.V. Burgen and J.F. Mitchell) 302; Guidelines For Parenteral Medication Usage (Gary S. Carl) 239; Index of Nutritional Abnormalities Induced by 50 Commonly Prescribed Drugs (IMA Publications Division) 302; Lithium in Medical Practice (F.N. Johnson and S. Johnson) 239; The Living State and Cancer (Albert Szent-Gyorgyi) 61; Management of Essential Hypertension (F. Gilbert McMahon) 116; The Office-Based Family Pharmacist (E.V. White) 785; Our Four Boys — Foster Parenting Retarded Teenagers (Martha Ufford Dickerson) 533; Pharmacy Technicians' Manual (Jane M. Durgin, Zachary I. Hanan, Charles O. Wea) 52; Pharmacy Technician Training Manual (L.P. Jeffrey) 614; Prescribers' Guide to Drug Interactions (Jack M. Rosenberg) 115; Principles and Perspectives in Drug Bioavailability (J. Blanchard, R.J. Sawchuk and B.B. Brodie) 531; Progress in Pharmacology (H. Grobeger) 785; Psychopharmacology (J.D. Barchas, P.A. Berger, R.D. Cincotta, and G.R. Elms) 50; Recent Advances in the Pharmacology of Adrenoceptors (E. Szabadi, C.U. Bradshaw and P. Bevan) 786; Self-Assessment of Current Knowledge in Clinical Pharmacy, Second Edition (Philip P. Gerbino) 530; Side Effects of Drugs (Dukes) 784; The SI for the Health Professions (World Health Organization) 365; Sourcebook on Unit Dose Drug Distribution Systems (American Society of Hospital Pharmacists) 366; Sports and Doping (P. Nijis) 51; 1978 Year Book of Dermatology (Frederic Malkinson and Roger W. Pearson) 366; 1978 Year Book of Drug Therapy (Daniel L. Azarnoff, Leo E. Hollister and David G. Shand) 301

Bosse, John A. (coauthor) see Higbee, Martin D., 24; (coauthor) Hypertension in Pediatrics 655

Boulard, Marc (coauthor) letter, see Reiss, Daniel, 610

Breast Milk, analgesics, 677; lithium, 494

Bromocriptine, in cardiovascular disease (CTF) 539; in general medicine (CTF) 788; in neurology (CTF) 540, 706; in obstetrics/gynecology (CTF) 439; in pulmonary disease (CTF) 624

Bruni, Giancarlo (coauthor) see Saputo, Vincenzo, 443

Bryan, Candace Kendle (author) book review, 784

Buffalo General Hospital, cimetidine study, 568

Buice, Robert G. (author) The Programmable Hand-Held Calculator — a powerful tool in clinical pharmacokinetics, 328; (author) letter, correction of error in programmable calculator article, 781

Burkhart, V. De P. (coauthor) see Powell, M.F., 506

Burkholder, David F. (author) Adverse Drug Effects and Their Impact on Patient Care, 421

Burke, Wayne S. (author) Allopurinol Hypersensitivity, 218

Butorphanol, in general medicine (CTF) 788

Butyrophenes, adverse reactions, mechanisms, and treatment, 198; as adjunct to lithium therapy, 407; use in PCP intoxications, 338

C

Caiola, Stephen M. (author) book review, 530

Calvert, Jon C. (coauthor) see Longe, R. Leon, 644

Canady, Bruce (author) letter, clarification of article on antiplatelet drugs, 451

Canafax, Daniel M. (coauthor) case report, phenytoin therapy in a pregnant epileptic: the role of pharmacokinetic monitoring, 534

Cancer Therapy see also Chemotherapy; Individual Drug Names; combination therapy, gynecocarcinoma and gonadal dysfunction (ab) 119; testicular (CTF) 706

Candidiasis, fluorocytosine treatment, 72; (case studies) 73, 74, 75; oral, caused by beclomethasone aerosol, 767; oral, treatment protocol, 489; oral, treatment with clotrimazole (ab) 295

Capmul 8210, in dissolution of gallstones (DIAS Rounds) 399

Capreosone, second-line antituberculosis therapy, 433

Carbamazepine, interaction with clonazepam (ab) 295

Carbaryl, in pediculosis treatment (DIAS Rounds) 398

Carbenicillin, ecthyma gangrenosum, 694; enhances aminoglycoside antibiotics (ab) 119

Carbon Dioxide, in Pop Rocks[®] and Cosmic Candy[®], 474

Carbon Monoxide, threshold of angina, 472

Carcinogens, governmental agencies basis for identification, 373

Cardiac Decompression see Heart Failure

Cardiovascular Disease, (CTF) antihypertensive agents, 439; aspirin, 705; beta-adrenergic blocking agents, 438, 539; DC counter shock, 705; digoxin, 438; diuretics, 787; dopamine, 539; heparin, 438, 539; nitroglycerin ointment, 705; nitroprusside, 705; phenolamine, 438; pindolol, 787; prazosin, 705; propranolol, 438; streptokinase, 787; ticrynafen, 438; verapamil, 438, 705; xipamide, 705

Cardiovascular System, effect of antipsychotic drugs, 200; prazosin, 212

Carlisted, Bruce C. (author) book review, 50

Case Reports, anaphylactic reaction in association with parenteral administration of clindamycin, 348; bleeding with continuous intravenous heparin infusion, 609; chloramphenicol-phenytoin drug interaction, 609; ecthyma gangrenosum, 692; hypercalcemia secondary to Tums[®], 350; neuroleptic withdrawal and vomiting, 350; Nicotolu's Syndrome from benzathine penicillin, 443; parenteral administration of clindamycin, 348; phenytoin therapy in a pregnant epileptic; the role of pharmacokinetic monitoring, 534; prazosin and the first-dose phenomenon, 444; pseudoresistance to amikacin, 537; three deaths due to hydrocodone in a resin-cough medicine, 445; topical-corticosteroid-induced cataracts, 537

Case Studies see Case Reports

Caustic Agents, in toxicology (CTF) 625

Cefaclor, in infectious disease (CTF) 788

Cefamandole, drug evaluation data, 144; in infectious disease (CTF) 540; pharmacokinetics in infants (ab) 550; pharmacokinetics in renal impairment (ab) 456

Cefazolin, compared to cephadrine (ab) 359; treatment of S. aureus endocarditis, 150

Cefoxitin, in aerobic and anaerobic infections (ab) 363; in infectious disease (CTF) 706, 788

Cefuroxime, in infectious disease (CTF) 438

Center for Disease Control, recommendations for syphilis treatment (DIAS Rounds) 160

Cephelothol, penetration into bone and synovial tissue (ab) 174

Cephadrine, compared to cefazolin (ab) 359; in pediatrics (CTF) 624; maternal-fetal transfer (ab) 295

Cerebrovascular disease, antiplatelet drugs decrease morbidity, 80

Chemo, inhibition of theophylline absorption (ab) 553

Chemotherapy, Cancer, see Cancer Therapy

China, health care delivery, 470

Chiu, Win L. (author) letter, creatinine VI, biological half-lives of creatinine in normal adults with different ages, 110

Chloramphenicol, decreases clearance of phenytoin and phenobarbital (ab) 171; in infectious disease (CTF) 438; in pediatrics (CTF) 624; interaction with phenytoin (case report) 609; pharmacokinetics (ab) 551

Chlorofluorocarbon, phaseout, 636

Chlorothiazide, in pediatric hypertension, 655

Chlorpheniramine, in pulmonary disease (CTF) 789

Chlorpromazine, treatment of postherpetic neuralgia, 356

Cholesterol, plasma concentration in diabetic patients (ab) 119

Cholestyramine, in pediatrics (CTF) 540; new analog of (ab) 174

Cholpor, description (ab) 174

Chromomycosis, fluorocytosine treatment, 72

Chymopapain, update, 557

Ciezkowski, Joe (coauthor) see Harper, J. Michael, 425

Cimetidine, in anesthesiology (CTF) 787; bioavailability (ab) 359; FDA statement, 557; impotence (ab) 293; in gastroenterology (CTF) 539, 623, 705; non-approved uses, 568; overutilization (letter) 43; pruritis (ab) 295; in pulmonary disease (CTF) 789; sexual dysfunction (ab) 455; uses, 567

Cinnarizine, antiasthmatic effects (ab) 458

Cinoxacin, pharmacokinetics (ab) 456

Cis-Retinoic acid, treatment of resistant acne (ab) 552

Clindamycin, and pleuropulmonary infections in children (ab) 458; colitis, induced (DIAS Rounds) 39; in obstetrics/gynecology (CTF) 624

Clinical Pharmacology, board certification (ed) 524; and clinical pharmacy (ed) 296, 310; outlined by World Health Organization, 274

Clinical Pharmacy, affected by physician glut, 448; American college, 564; aspirations, 211; and clinical pharmacology (ed) 296, 310; and community pharmacist, 347; contribution of Donald E. Francke (ed) 163; definition, 272; drug product selection (ed) 448; expanded role for the community pharmacist, 351; future direction, 233; model for institutional role, 282; potential clinical role, 291; professional unity, 210; public opinion of pharmacists, 211; rate of growth, 209; record of activities, 282; reducing drug usage in a community hospital, 266; research needs and priorities, 669; role in dental therapy, 486; services, (letter) 44

Clinical Training, see Pharmacy Education

Clobazam, symposium (ab) 456

Clofazimine, in dermatology (CTF) 539

Clofibrate, acute muscular syndrome (ab) 454; as antiplatelet agent, 80; contraindication in coronary artery disease therapy (letter) 451; gallstone induction (ab) 118; kinetics (ab) 121; new regulations, 636

Clomiphene, in obstetrics/gynecology (CTF) 706

Clonazepam, compared with desipramine and L-tryptophan, 392

Clonazepam, interaction with carbamazepine (ab) 295

Clonidine, apnea following overdose, 778; in endocrinology (CTF) 705; in neurology (CTF) 788; in pediatric hypertension, 658; withdrawal syndrome (ab) 362

Clorazepate, in neurology (CTF) 439

Closson, Richard G. (coauthor) see Solomon, David K., 669

Clostrimazole, in infectious disease (CTF) 540; oral candidiasis (ab) 295

Cloutier, Gilles (author) letter, criticism of phenytoin 300 mg daily article, 167

Clozapine, in psychiatry (CTF) 540

Colchicine, in gastroenterology (CTF) 787

Colistin, ecthyma gangrenosum, 694

Collins, G. Edward (coauthor) letter, see Stewart, Clinton, 165

- Combination Therapy, chemotherapy, adverse reactions, (ab) 119; clinical importance, 153
- Community Practice see Clinical Pharmacy
- Compliance see Patient Compliance
- Computer, system for monitoring drug therapy, 166; the calculator as a tool in pharmacokinetics, 328; used to detect adverse drug reactions, 774
- Congenital Malformation see Teratogenesis
- Congestive Heart Failure, treatment with dobutamine, 728
- Congress, current news, 474, 717
- Conner, Christopher S. (coauthor) Drug Information — the problems and some solutions, 86; (coauthor) see Grabert, Brian, 778; (co-editor) Current Therapeutic Findings, 437, 539, 623, 705, 787
- Consultation see Pharmacist Consultation
- Consumer Product Safety Commission, basis for identifying possible carcinogens, 373
- Contact Lens, for post-cataract patient, 635
- Conte, John (author) letter, pediatric medicine clarified, 452
- Continuing Education, "mini-residency" in drug information, 603
- Coronary Artery Disease, and antiplatelet drugs, 81
- Corrections, in *Applied Therapeutics for Clinical Pharmacists*, 2nd Ed., Chapter 33, "Anemias" (letter) 354; to 5-fluorouracil article (letter) 598; to programmatic calculator article (letter) 781
- Corticosteroids see Steroids
- Cortopassi, Ronald F. (coauthor) case report, pseudoresistance to amikacin, 537
- Cosmetic Injuries, Nelson report, 308
- Cost, effect on prescribing patterns, 156; maximum allowable (MAC) 156
- Cotrimoxazole, childhood UTI (ab) 57; in pediculosis treatment (DIAS Rounds) 398
- Counseling see Pharmacist Consultation; Clinical Pharmacy
- Courchesne, Yves (author) letter, comment on French abstracts, 603
- Covinsky, Joel O. (author) book review, 364; (coauthor) see Park, Glen D., 728
- Cradock, James C. (coauthor) see Trissel, Lawrence A., 340
- Creatinine Clearance, estimation from serum creatinine clearance (letter) 110, authors' reply, 111
- Crom, William R. (coauthor) book review, 613
- Cromolyn Sodium, in general medicine (CTF) 788
- Cryptococcosis, fluorocytosine treatment, 72
- Cupit, Gary C. (editor) DIAS Rounds 38, 160, 260, 397; (coauthor) DIAS Rounds see Rubenstein, Elan, 160; Grady, Cathy, 261
- Current Therapeutic Findings, 437, 539, 623, 705, 787
- Cyclacillin, compared to ampicillin (ab) 359
- Cyclameter, current FDA status, 375; update, 636
- Cycloheximide, in dermatology (CTF) 705
- Cyclophosphamide, in cardiovascular disease (CTF) 623; in oncology (CTF) 540; in ophthalmology (CTF) 624
- Cycloplegics, in ophthalmology (CTF) 439
- Cycloserine, second-line antituberculosis therapy, 433
- Cytosine Arabinoside, in oncology (CTF) 788; treatment of disseminated herpes zoster, 258
- D**
- Dahlin, Patricia A. (author) letter, comments on judicial views article, 451
- D'Angelo, Angelo C. (author) book review, 785; (ed) The Family Pharmacist, 347
- Dantrium[®] see Dantrolene
- Dantrolene, malignant hyperthermia (DIAS Rounds) 40; (letter) 297; (CTF) 705
- Dasta, Joseph F. (author) Metoprolol-Drug Evaluation Data, 320
- Davignon, J. Paul (coauthor) see Trissel, Lawrence A., 340
- Davis, Larry J. (editor) DIAS Rounds, 38, 160, 260, 397, 596; (coauthor) DIAS Rounds see Honda, Dennis H., 38; Bernstein, Linda R., 40; Sandow, Neil L., 160; Ryll, Chuck, 260; Potter, S. Kip, 397; Fang, Emily N., 596; Watanabe, Joyce C., 597
- Deferoxamine, in hematology (CTF) 438
- De Haen, Paul (author) letter, critique of critic's book review, 450
- Deiner, Carl H. (author) letter, hospital pharmacy survey, 357
- Delafuente, Jeffrey C. (coauthor) Pharmacologic Aspects of Immunization, 385
- Dentistry, pharmacy involvement, 486
- 2-deoxy-D-glucose, in obstetrics/gynecology (CTF) 624
- Department of Health, Education, and Welfare, maximum allowable cost regulations, 156
- Depression, lithium therapy, 405
- Dermatology (CTF) clofazimine, 539; cycloheximide, 705; methoxsalen, 787; neomycin, 787; tretinoin, 539, 787
- Desagné, Marc (author) letter, comment on French abstracts, 698
- Desipramine, compared with clomipramine and L-tryptophan, 392; compared with lithium in treatment of acute depression, 405; in psychiatry (CTF) 439
- Dexamethasone, and cataract formation (case report) 538; in hematology (CTF) 438; in neurology (CTF) 788; prevention of respiratory distress syndrome (DIAS Rounds) 161, (letter) 526
- Dextran, as antiplatelet drug, 80; in intravenous therapy (CTF) 624; in obstetrics/gynecology (CTF) 439
- Dextrothyroxine, in endocrinology (CTF) 623
- Diabetes, drug compliance, 141; drug-taking behavior of diabetic patients, 506; plasma cholesterol levels (ab) 119
- Diapamide, compared to furosemide (ab) 552
- DIAS Rounds, alpha-MPT and pheochromocytoma, 597; amiodarone in ventricular arrhythmia, 397; antiemetics in myelography, 262; Capmul 8210, 399; clindamycin colitis, mechanism of, 39; dantrolene in malignant hyperthermia, 40; drug interference with evaluation of pheochromocytoma, 261; glucocorticoids in the treatment of respiratory distress syndrome, 160; lidocaine, intraarterially in angiography, 596; methylphenidate rhabdomyolysis, 161; minocycline and black thyroid, 261; neurosyphilis, treatment of, 160; pediculosis treatment, 398; pyridoxine for the treatment of rheumatoid arthritis, 38; sodium valproate and hair loss, 597; warfarin-disopyramide interaction, 260
- Diazepam, anticid effect on (ab) 172; effect on albumin-bilirubin binding, 500; food effect on (ab) 172; identification of precipitate (letter) 612; in intravenous therapy (CTF) 624; in pediatrics (CTF) 439; in toxicology (CTF) 625; in urology (CTF) 440
- Diazoxide, in pediatric hypertension, 660; treatment of hypokalemic periodic paralysis, 328
- Dibromochloropropene (DBCP), update, 558
- Diet, in nutrition (CTF) 788
- Diethylstilbestrol, current FDA status, 375
- Diffusional, and renal insufficiency (ab) 457; uricosuric effects (ab) 457
- Digoxin, absorption decreased by kaolin-pectin (ab) 171; effect on albumin-bilirubin binding, 500; in cardiovascular disease (CTF) 438; questions and answers (letter) 700; quinidine interaction (case study) 286; toxicity, 287
- Dihydroergotamine, in psychiatry (CTF) 706
- 1,25 Dihydroxycholecalciferol, in pediatrics (CTF) 540
- Dimethyl Sulfoxide, FDA update, 475
- Dimick, Alan (coauthor) see Stewart, Clinton, 692
- Dioxins, FDA update, 477
- Diphosphonate, in urology (CTF) 440
- Diphtheria, immunization, 388
- Dipyridamole, as antiplatelet agent, 80
- Disopyramide, agranulocytosis (letter) 165; in obstetrics/gynecology (CTF) 540; interaction with warfarin (DIAS Rounds) 260
- Dispensing, good practices update (ed) 802
- Dispensing Information see USP
- Disulfiram, decreases clearance of benzodiazepines (ab) 119
- Diuretics see also Individual Drug Names, in cardiovascular disease (CTF) 787; in pediatrics, 654; treatment of periodic hypokalemic paralysis, 325
- Dobutamine, cardiovascular effects (ab) 57; compared to dopamine, 728; compared to isoproterenol, 728; compared to nitroprusside, 728; pharmacokinetics, 728, 174
- Doctor of Pharmacy see also Pharmacy Education, debate (letter) 110; issue over, 210
- Dodds, Arthur W. (coauthor) The Clinical Pharmacist's Role — a National Survey Finding, 290
- Dodds, Linda (author) book review, 52
- Domperidone, in pediatrics (CTF) 540
- Dopamine, compared to dobutamine, 728; in anesthesiology (CTF) 438; in cardiovascular disease (CTF) 539, 705; treatment of clonidine overdose, 778
- Doxapram, pharmacokinetics (ab) 363
- Doxepin, in psychiatry (CTF) 624
- Doxycycline, in infectious disease (CTF) 788
- DPT Vaccine, withdrawn, 476
- Drew, John H. (coauthor) The Effects of Drugs on Albumin Binding of Bilirubin and On Free Bilirubin Concentration as Determined by Fluorescence Quenching, 498
- Droperidol, in anesthesiology (CTF) 787; in oncology (CTF) 624
- Drug Actions, Interactions and Reactions, 56, 118, 171, 293, 358, 454, 549
- Drug Development, economic disincentives, 193
- DRUGDEX[®], 86
- Drug Distribution Systems, unit dose to prevent medication errors (ed) 720
- Drug Evaluation Data, cefamandole, 144; valproic acid, 18
- Drug Industry see Pharmaceutical Industry
- Drug information, alternative sources, 512; for dental students, 488; "mini-residency" for the practicing pharmacist, 603; public system, Nov-Ctr 1; USP Drug Product, Problem Reporting Program, toll free number, Nov-Ctr 1
- Drug Interactions, computer system (letter) 166; corticosteroids and enzyme inducers, 577; criteria for classification, 268; judging their significance (letter) 450; author's reply, 450; retrospective study, phenytoin—chloramphenicol, 425; USPHS advisory for alcohol, 537
- alcohol-warfarin (CTF) 625
- acetaminophen-epileptic drugs (ab) 549
- aluminum hydroxide-ethambutol (ab) 358
- aminoglycoside antibiotics-carbenicillin (ab) 119
- aminoglycoside antibiotics-piperacillin (ab) 119
- aminoglycoside antibiotics-ticarcillin (ab) 119
- antacid-diazepam (ab) 172
- antacid-prednisone (ab) 454
- aspirin-propranolol (ab) 549
- asthma in children-corticosteroids (ab) 358
- barbiturates-corticosteroids, 577
- benzodiazepine-disulfiram (ab) 119
- bran-digoxin (CTF) 625
- calcium/antacid-phenytoin (CTF) 625
- carbamazepine-clonazepam (ab) 295
- carbamazepine-dexamethasone, 578
- carbenicillin-aminoglycoside antibiotics (ab) 119
- carbido-tryptophan, 394
- cephalothin-gentamicin, 150
- chloramphenicol-phenobarbital (ab) 171
- chloramphenicol-phenytoin (ab) 171, 425, 609
- cimetidine-oral anticoagulants (CTF) 707
- clonazepam-carbamazepine (ab) 295
- clonidine-fluphenazine (CTF) 440
- contraceptives-smoking (ab) 56
- corticosteroids-asthma in children (ab) 358
- corticosteroids-barbiturates, 577
- corticosteroids-enzyme inducers, 577
- corticosteroids-phenytoin, 577
- corticosteroids-primidone, 577
- corticosteroids-rifampin, 578
- dexamethasone-carbamazepine, 578
- diazepam-antacid (ab) 172
- diazepam-food (ab) 172
- digoxin-bran (CTF) 625
- digoxin-kaolin-pectin (ab) 171
- digoxin-quinidine (CTF) 440
- digoxin-quinidine (CTF) 625
- disopyramide-warfarin (DIAS Rounds) 260
- disulfiram-benzodiazepine (ab) 119
- edrophonium-pancuronium (CTF) 707
- enzyme inducers-corticosteroids, 577
- epileptic-drugs-acetaminophen (ab) 549
- ethambutol-aluminum hydroxide (ab) 358
- ethambutol-glycopyrronium (ab) 358
- fluphenazine-clonidine (CTF) 440
- food-diazepam (ab) 172
- furosemide-probenicid (ab) 171
- gentamicin-cephalothin, 150
- glycopyrronium-ethambutol (ab) 358
- indomethacin-probenicid (ab) 172
- indomethacin-lithium (CTF) 440
- iodine-containing products-lithium, 495
- isoniazid-phenytoin (ab) 454; (CTF) 541
- lithium-pectin-digoxin (ab) 171
- lithium-indomethacin (CTF) 440
- lithium-iodine-containing products, 495
- lithium-thiazide diuretics, 495
- magnesium-aluminum hydroxide antacid-theophylline (CTF) 707
- nicotinamide-tryptophan, 393
- oral anticoagulants-cimetidine (CTF) 707
- pancuronium-edrophonium (CTF) 707
- phenobarbital-chloramphenicol (ab) 171
- phenytoin-calcium/antacids (CTF) 625
- phenytoin-chloramphenicol (ab) 171, 425, 609
- phenytoin-corticosteroids, 577
- phenytoin-isoniazid (ab) 454; (CTF) 541
- phenytoin-valproic acid (CTF) 541
- piperacillin-aminoglycoside antibiotics (ab) 119
- povidone-iodine-urine test (CTF) 707
- prednisone-antacids (ab) 454
- primidone-corticosteroids, 578
- probenicid-furosemide (ab) 171
- probenicid-indomethacin (ab) 172
- propranolol-aspirin (ab) 549
- propranolol-quinidine (CTF) 625
- quinidine-digoxin (CTF) 440; (CTF) 625
- quinidine-propranolol (CTF) 625
- rifampin-corticosteroids, 578
- smoking-contraceptives (ab) 56
- theophylline-magnesium-aluminum hydroxide antacid (CTF) 707
- thiazide diuretics-lithium, 495
- ticarcillin-aminoglycoside antibiotics (ab) 119
- trimethoprim-sulfamethoxazole-warfarin (CTF) 541
- tryptophan-carbido, 394
- tryptophan-nicotinamide, 393
- urine test-povidone-iodine (CTF) 707
- valproic acid-phenytoin (CTF) 541
- warfarin-alcohol (CTF) 625
- warfarin-disopyramide (DIAS Rounds) 260
- warfarin-trimethoprim-sulfamethoxazole (CTF) 541
- Drug Interactions Update (column) Corticosteroids and Enzyme Inducers, 577**
- Drug Manufacturers see Pharmaceutical Industry**
- Drug Packaging, unit-of-use packaging, 227; USP requirements, 225**
- Drug Prescribing see Prescribing**
- Drug Product Selection Acts, update, 556**
- Drug Regulation Reform Act, a critique, 193; adverse drug effects, 424; congressional proposals for 1979 version, 474; update, 800**
- Drug Resistance, failure of disc sensitivity-testing with resistant bacteria (case report) 537**
- Drug Therapy see Cancer Therapy; DIAS Rounds; Disease State; Individual Drug Names**
- Drug Therapy Monitoring, computer system (letter) 166; evaluation of dosing, regimens for insulin in diabetic ketoacidosis, 572; in nursing facilities (letter) 298**
- Drugs, Adverse Reactions see Adverse Drug Reactions; Adverse Reactions**
- Drugs, Interchangeable, Massachusetts, 476**
- Dunnebacke, Robert (coauthor) see Self, Timothy H., 96**
- Duodenal Ulcers, cimetidine, 568**
- Dysmenorrhea, naproxen and indomethacin, 676**
- Dysphoria, antipsychotic drug reaction, 203**
- Dystonia, antipsychotic drugs, 204**
- E**
- Easton, Margaret (coauthor) letter, survey of written drug information, 699
- Eckel, Frederick M. (coauthor) see Hardie, Nancy Richardson, 588
- Ecthyma Gangrenosum, carbenicillin, colistin, gentamicin, ticarcillin, tobramycin, 694
- Edema, pulmonary, ethchlorvynol-induced, 98
- Editorials
- George F. Archambault, Clinical Pharmacist or Clinical Pharmacologist? 310; GMP, GDP, and Unit-of-Use — An Update, 802; Infection Control in Hospitals — What Role Does Pharmacy Play?

- 638; The KI "Solution," 478; Metrication, 376; They'll Come Marching In . . . 560; Unit Dose System Can Prevent Medication Errors - Only If Monitored Properly, 720; Why at 70? Because! 232
- Angele C. D'Angelo, The Family Pharmacist, 347
- Donald C. McLeod, A Health Priority: Continued Innovation in Pharmaceutical Industry and Practice, 447; Board Certification in Clinical Pharmacology: Bane or Boon?, 524; Donald E. Francke and Clinical Pharmacy, 163; Future Direction of Drug Intelligence and Clinical Pharmacy, 233; The European Society of Clinical Pharmacy, 691
- John A. Owen, Introducing USP Update, 523
- Paul G. Pierpaoli, The Physician's Glut - What Does it Portend for Clinical Pharmacy?, 448
- George P. Provost, In Memoriam: Donald E. Francke, 163
- Harvey A.K. Whitney, Jr., Asleep at the Switch, 232; Biomedical Journal Uniformity, Double Issue, and Other New Developments, 449; Pharmacy and Pharmacology: Importance of Collaboration at the Clinical Level, 296; The Creation of the American College of Clinical Pharmacy, 608; The Human Side of a Pharmacy Resident, 108; The Journal for Drug Therapy Decision Makers, 479; Unit-of-Use Packaging Will Eliminate the Last Vestige of the Old Era, 234
- William A. Zellmer, Donald E. Francke (memoriam) 164
- Editorial Policy**, on reviewing review articles (letter) 357, author's reply, 357; questioning necessity for faculty coauthorship (letter) 528
- Education, see Patient Counseling; Pharmacy Education**
- Elenbaas, Robert M. (author) book review, 532
- Endocarditis, methicillin-resistant *S. aureus* (case study) 152
- Ensworth, Stephanie (author) letter, morphine IV infusion for chronic pain, 297
- Endocrinology (CTF) clonidine, 705; fructose, 705; imipramine, 438; oxandrolone, 438; phenytoin, 787
- Environmental Protection Agency, basis for identifying possible carcinogens, 373
- Eoff, James C. (coauthor) see Self, Timothy H., 282
- Epilepsy, caused by antipsychotic drugs, 203; phenytoin dosage (letter) 167; phenytoin therapy in a pregnant epileptic (case report) 534
- Epinephrine, in pulmonary disease (CTF) 624
- Ereshefsky, Larry (author) book review, 239; (coauthor) Lithium Therapy of Manic Depressive Illness-Part I: Target Symptoms Pharmacology and Kinetics, 403; (coauthor) Lithium Therapy of Manic Depressive Illness-Part II: Monitoring, 492
- Errors, Medication, prevented by unit dose (ed) 720
- Erythromycin, ABE prophylaxis, 488; hepatotoxicity (case study) 236; in infectious disease (CTF) 706; neurosyphilis treatment (DIAS Rounds) 160; induced hepatotoxic reaction (letter) 612
- Esterogens see also Oral Contraceptives, conjugated, in psychiatry (CTF) 439; endometrial cancer (ab) 293; and incidence of endometrial cancer (ab) 550; in oncology (CTF) 706
- Ethacrynic Acid, in pediatric hypertension, 655
- Ethambutol Hydrochloride, tuberculosis therapy, 432
- Ethaverine, new drug status, 558
- Ethchlorvynol, induced pulmonary edema (case study) 96
- Ethionamide, second-line antituberculous therapy, 433
- Ethylene Oxide, in toxicology (CTF) 625
- Etomidate, in anesthesiology (CTF) 539
- Evans, David C. (coauthor) see Hart, Linda L., 414
- Evans, William E. (coauthor) book review, 613
- Evens, Ronald P. (coauthor) letter, see Harden, Tom C., 109; (author) letter, renacidin irrigation, 165
- Extrapyramidal System, antipsychotic drugs, adverse reactions, 203
- F**
- Fang, Emily N. (coauthor) DIAS Rounds, intraarterial lidocaine in angiography, 596
- Fat Emulsion, in intravenous therapy (CTF) 540
- Feldman, Marvin J. (coauthor) letter, dexamethasone for respiratory distress, 526
- Fenoprofen, aspirin alternative, 675
- Fentanyl, in anesthesiology (CTF) 438
- Ferrous Sulfate, in hematology (CTF) 705
- Pink, Joseph L. III (author) Judicial Views of the Pharmacist's Professional Status, 30
- Fischer, Richard G. (coauthor) Beclomethasone Dipropionate Aerosol: Patient Consultation Recommendations, 767
- Flesch Formula, pertinence to PPI readability (letter) 355; author's response, 356
- Flecetofen, metabolism (ab) 359
- Florida A & M University, recipient of HEW grant, 799
- Floyd, Ronald A. (coauthor) letter, serum drug level usage review - a clinical pharmacy service, 45
- Fluorescence Quenching, to determine drug effects on albumin and bilirubin binding, 498
- Fluoridation, new program, 637
- 5-Fluorouracil, in infectious disease (CTF) 624; (letter) 698
- Fluorouracil, in oncology (CTF) 439
- Food, effect on bioavailability of 8-methoxysalen (ab) 551
- Food Additives, polychlorinated biphenyls, 636
- Food and Drug Administration, and the Three-Mile Island nuclear crisis (ed) 478; basis for identifying possible carcinogens, 373; clinical guidelines, 307; dimethyl sulfoxide update, 475; establish antibiotic monograph subcommittee with USPC, Sept-ctr 3; investigation of chewable vitamins with iron overdoses, 473; investigation of "Pop Rocks" and "Cosmic Candy," 474; Neis report on hospital emergency cases of cosmetic injuries, 308; non-FDA approved drug indications (letter) 109; patent of fenses, 193; patient package inserts, 292, FDA proposals for, Sept-ctr 1; proposed PPI regulation, Sept-ctr 1; proposes PPI, 555; recommendations for labeling OTC vitamin and mineral supplements, 473; six drugs and chemical updates, 375; synthetic hair implants, 717; therapeutic equivalence list, 374
- Ford, William M. (author) letter, cimetidine treatment of pruritus, 611
- Fountain, Francis F. (coauthor) see Self, Timothy H., 96
- Francke, Donald E. (author) Relationship Between Clinical Pharmacology and Clinical Pharmacy, 272; founder of ASHP (ed) 164
- Fraser, Donald G. (coauthor) DIAS Rounds, pediculosis treatment, 398; (author) DIAS Rounds, alpha-MPT and pheochromocytoma, 597
- Freeman, Debra (coauthor) DIAS Rounds, minocycline and black thyroid, 261
- French, David M. (coauthor) see Luckman, Roger, 136
- Fritz, John N. (author) see Hart, Linda L., 414
- Fructose, in endocrinology (CTF) 705
- Furosemide, adverse reactions in cirrhosis (ab) 454; compared to diazepam (ab) 552; effect on albumin-bilirubin binding, 500; in pediatric hypertension, 655; pharmacokinetics, 655; response affected by probenecid (ab) 171
- G**
- Gagnon, Jean P. (coauthor) see Zelnio, Robert N., 156; (coauthor) see Hardie, Nancy Richardson, 588
- Gainesville Drug Study Group, chloramphenicol-phenytoin interaction, 429
- Galactorrhea, antipsychotic drugs, 200
- Galinsky, Raymond E. (coauthor) letter, comments on constant blood withdrawal method for obtaining AUC, 781; author's reply, 781
- Gamma Benzene Hexachloride, GBH, in pediculosis treatment (DIAS Rounds) 398
- Gastroenterology (CTF) aminophylline, 539; anti-diarrheal agents, 539; aspirin, 438; cimetidine, 539, 705, 787; colchicine, 787; hydrocortisone, 787; pancreatic enzymes, 539; ursodeoxycholic acid, 787; vasopressin, 787; zinc sulfate, 539
- Gee, Joseph P. (coauthor) A Prospective Review of Cimetidine Use, 567
- Gehrig's Disease see Amyotrophic Lateral Sclerosis
- General Medicine (CTF) benzodiazepines, 438; bromocriptine, 787; butorphanol, 787; cromolyn sodium, 787; dextranomer, 705; propranolol, 788
- Gentamicin, comparison with netilmicin in newborns (ab) 552; ecthyma gangrenosum, 694
- Gephart, William K. (coauthor) DIAS Rounds, an-demetics in myelography, 262
- Gilderman, Alexander M. (coauthor) see Ereshefsky, Larry, 403, 492
- Giusti, Donald L. (coauthor) see Cortopassi, Ronald F., 537
- Glaucoma, benzodiazepine use (letter) 109
- Glucose, in pediatrics (CTF) 439
- Goldstein, Eric (author) book review, 533
- Good Dispensing Practices, update (ed) 802
- Good Manufacturing Practices, update (ed) 802
- Gonorrhea, antibiotic treatment in pregnancy (CTF) 705; infectious disease (CTF) 705; prophylaxis with minocycline (ab) 550
- Goyan, Jere Edwin, FDA commissioner, 558, 799, 801
- Grabert, Brian, (coauthor) Clonidine: Recurrent Apnea Following Overdose, 778
- Grady, Cathy (coauthor) DIAS Rounds, drug interference with evaluation of pheochromocytoma, 261
- Grants, Office of Education awards, 799
- Greehey, Barbara L. (coauthor) see Fraser, Donald G., 398
- Greenlaw, Cal W. (author) case report, chloramphenicol-phenytoin drug interaction, 609; (coauthor) letter, hepatotoxicity possibly associated with erythromycin ethylsuccinate, 236; (coauthor) Successful Treatment of Apparent Methicillin-Resistant *S. aureus* Endocarditis with Gentamicin and Cephalothin, 150
- Greiner, Gary E. (author) letter, why not more pharmacists?, 235
- Grogan, F. James (author) letter, antileptel drugs: comment, 451; (author) The Hospital Pharmacist and Nursing Pharmacology, 664
- Grossman, Joshua B. (author) letter, advising the patient, 110; (author) letter, questions and answers on the use of digitalis preparations, 700
- Guafenesin, contraindications in primary hemostatic disorders (letter) 452
- Guanethidine, in neurology (CTF) 624
- Gudauskas, Gedy (coauthor) see Massoud, Neil, 266
- Guernsey, Brock G. (coauthor) Multi-Drug-Resistant Pulmonary Tuberculosis: A Continuing Problem, 430
- Guidelines, for preparing DICP manuscripts, 4, 379, 642, 722
- Guillard, Oliver (coauthor) letter see Reiss, Daniel, 610
- Gynecostasia, induced by spironolactone (ab) 118; with combined chemotherapy (ab) 119
- H**
- Hair Implants, synthetic, adverse reactions, 717
- Haloperidol, in psychiatry (CTF) 788; in toxicology (CTF) 789
- Hanna, Michael E. (coauthor) see Pomerance, Alan J., 348
- Harden, Tom C. (author) letter, benzodiazepine use in glaucoma, 109
- Hardie, Nancy Richardson (coauthor) Feasibility of Symbolic Directions on Prescription Labels, 588
- Harper, J. Michael (coauthor) Phenytoin-Chloramphenicol Interaction, 425
- Harrison, Willard L. (coauthor) see Pomerance, Alan J., 348
- Hart, Linda L. (coauthor) The Clinical Pharmacist on an interdisciplinary Primary Health Care Team, 414
- Hayton, William L. (coauthor) authors' reply see Lott, Rex S., 111
- Health Care Delivery, clinical pharmacist on an interdisciplinary primary health care team, 414; cost effectiveness, 418; expanded role for the community pharmacist, 351; in China, 470; pharmaceutical industry and (ed) 447; relationship of knowledge and compliance, 508; Surgeon General talks on goals of, 383
- Health Care Sociology, factors in contemporary medicine that undermine moral values (ab) 60; female and male medical students-difference in specialty choice (ab) 61; health of the world's children (ab) 627; judgments of trained observers on adverse drug reactions (ab) 626
- Health Manpower Shortage, report, 475
- Health Systems Agencies (HSA), new regulations, 635
- Heart Disease see Cardiovascular Disease
- Heller, William M. (author) Nongovernment Alternatives to Unit-of-Use Packaging, 225
- Helling, Dennis K. (coauthor) see Walker, John A., 486
- Hematology, (CTF) aspirin, 540; deferoxamine, 438; dexamethasone, 438; ferrous sulfate, 705
- Hemodialysis, in urology (CTF) 625
- Henrietta, Geoffrey C. (coauthor) letter see Greenlaw, Cal W., 236
- Heparin, bleeding with continuous iv infusion (case report) 609; in cardiovascular disease (CTF) 438, 539; prevention of deep-vein thrombosis, 78; treatment of Nicolau's syndrome (case report) 443
- Hepatic Cell Adenoma see Liver Tumors
- Hepatotoxicity see also Liver; with erythromycin ethyl succinate (case study) 236; (letter) 612
- Hermann, Joachim J. (author) Phosphate: Its Valence and Methods of Quantification in Parenteral Solutions, 579
- Herpes Simplex, encephalitis, vidarabine treatment, 256; levamisole therapy (ab) 551
- Herpes Zoster, treatment, 255
- Hetzl, David J. (author) letter, cimetidine ad-nauseam?, 354
- HEW, change to Health and Human Services (HHS), 799; endorses HMOs, 554; Harris appoints new secretary, 558; 1979 health report, 554; report on marijuana and health, 555
- Hicks, Charles I. (author) letter, University of Toledo Pharmacy Seminar, 529
- Higbee, Martin D. (coauthor) Apnea of Prematurity, 24
- HMOs, endorsed by HEW, 554; new rules by FDA, 717
- Hoar, Marion E. (coauthor) letter see Hoar, Nancy, 355
- Hoar, Nancy (coauthor) letter PPI readability, 355
- Hohenwarter, Mark (coauthor) letter see Thompson, Dennis, 781
- Holloway, Donald (author) book review, 365
- Honda, Dennis H. (coauthor) DIAS Rounds, medical treatment of rheumatoid arthritis, 38
- Hood, Jerry C. (coauthor) Use of Computer Drug-Drug Interaction Program for Detection of Adverse Drug Reactions, 774
- Hopfel, Alan W. (author) Treatment of Disseminated Herpes Zoster Infections, 255
- Horn, John R. (author) book review, 51; (author) book review, 115; (author) letter reviewer's position explained, 450
- Hospital Pharmacy see Clinical Pharmacy
- Hovander, Greg (author) Recent Alternatives to Aspirin, 673
- Howie, Denise L. (author) book review, 170
- Huber, Joseph W. III (coauthor) see Raymond, Glynn, 612
- Human Diploid Vaccine, in toxicology (CTF) 440
- Hydralazine, in cardiovascular disease (CTF) 623; in pediatric hypertension, 658
- Hydrochlorothiazide, in pediatric hypertension, 655
- Hydrocodone, overdose (case report) 445
- Hydrocortisone, for intraoral aphthous, 490; in gastroenterology (CTF) 787
- Hydroxyzine, suppression of allergic rhinitis (ab) 549
- Hyperalimentation, enteral (ab) 553; in pediatrics (CTF) 439
- Hyperkinesia, study results, FDA, 307
- Hypertension, drug compliance, 141; in pediatrics, 653; use of nadolol (ab) 552
- Hyperthermia, dantrolene, use of (DIAS Rounds) 40
- Hyperthyroidism, (case study) 645
- Hypokalemia, hypokalemic periodic paralysis (case study) 323; with insulin therapy, 575
- Hypotension, effect of antipsychotic drugs, 199
- Hypotensive Agents, in cardiovascular disease (CTF) 539; patient compliance, 471
- I**
- Ibuprofen, aspirin alternative, 674; compared to sulindac, 736
- Ifosfamide, investigational drug information, 340
- Imipramine, comparison with lithium in treatment of acute depression, 405; in endocrinology (CTF) 438; in urology (CTF) 440
- Immunization, active agents used for, 387; for infants and children, 388; overview for the clinical phar-

macist, 385; passive agents used for, 387
Immunotherapy, in dermatology (CTF) 623
Impotence, cimetidine (ab) 293
Indexing, list of systems, 513
Indomethacin, for dysmenorrhea, 676; in pediatrics (CTF) 706; probenecid improves response to (ab) 172
Industry, see Pharmaceutical Industry
Infection Control, pharmacy's role (ed) 638
Infectious Disease, (CTF) amoxicillin, 788; ampicillin, 540; bacampicillin, 788; cefaclor, 788; cefamandole, 540; cefoxitin, 706; 788; cefuroxime, 438; chloramphenicol, 438; clotrimazole, 540; doxycycline, 788; erythromycin, 706; gonorrhea, 705; levamisole, 788; metronidazole, 788; miconazole, 706; minocycline, 438; povidone-iodine, 438; prophylactic antibiotics, 705; rifampin, 439; vancomycin, 706; vidarabine, 439
Influenza, immunization, 389
Injection, see Intravenous Therapy
Inoue, Fumio (author) Adverse Reactions of Antipsychotic Drugs, 198
Insulin, brain tryptophan levels, 391; in endocrinology (CTF) 623; pharmacokinetics, 573; regimens in diabetic ketoacidosis, 572
Interferon, treatment of varicella-zoster infection, 258
Intravenous Solutions, zinc contamination (ab) 56
Intravenous Therapy (CTF), albumin, 439; fat emulsion, 540; nitroglycerin, 540
Ishit, Arthur (author) letter, non-FDA approved drug indications, 109
Iso-carboxamid, with L-tryptophan, 392
Isoniazid, febrile reactions (ab) 358; tuberculosis therapy, 432
Isoquinoline, in neurology (CTF) 540
Isoproterenol, compared to dobutamine, 728; in ophthalmology (CTF) 439
Ivey, Marianne F. (coauthor) A "Mini-Residency" in Drug Information for the Practicing Pharmacist, 603

J

Jacobs, Richard S. (author) letter, possible overutilization of cimetidine, 43
Jackson, Eric A. (author) book review, 301
Jamson, H. Douglas (coauthor) see Canafax, Daniel M., 534
Japan, Pharmaceutical Affairs Law, 477
Jaundice, antipsychotic drugs, 701
Jerome, Micky (author) Hypokalemic Periodic Paralysis—the Syndrome and its Treatment, 323
Jewett, Christina M. (coauthor) see Ereshefsky, Larry, 403, 492
Jim, Lucia K. (coauthor) see Gee, Joseph P., 567
Jinks, Martin (author) book review, 302
Johnson, Curtis A. (coauthor) see Schultz, David W., 350
Johnson, Richard (author) letter, physical assessment articles praised, 166
Joint Commission on Accreditation of Hospitals (JCAH), outpatient care programs, 717
Jones, Edward H. (author) letter, problems with metrication, 611
Jordan, P. Sean (author) book review, 170
Journals Reviewed, Enzyme and Microbial Technology (J.F. Kennedy and O.R. Zaborsky), 54; Medicolegal News (American Society of Law and Medicine, Inc.), 54; Pharmacy Management (George P. Provost), 54; Sociology of Health and Illness (Alan Davis and Ray Jobling), 117
Judicial Views, of the pharmacist's professional status, 30

K

Kanamycin, second-line antituberculosis therapy, 433
Kaolin-Pectin, dioxin absorption decreased (ab) 171
Kaestn, Gregory W. (author) letter, more on prazosin, 527
Katz, Seymour (author) letter, more on "why not more pharmacists," 298
Kaul, Alan F. (coauthor) letter see Feldman, Marvin J., 526
Kearns, Gregory L. (author) book review, 615
Ketoacidosis, dosing regimens of insulin, 572
Keys, Philip W. (coauthor) letter, dosing adjustments of aminoglycoside antibiotics, 44
Kinetics, see Pharmacokinetics
King, Christine (coauthor) DIAS Rounds, clindamycin-induced colitis, 39
King, James (coauthor) see Luckman, Roger, 136
KI Solution, see Potassium Iodide
Kleinman, Larry M. (coauthor) see Trissel, Lawrence A., 340
Kolb, Mary Elizabeth (coauthor) letter see Martz, Robert C., 297
Kong, Cheung Tung (author) letter, a computer system for monitoring patient medications, 166
Korberly, Barbara (coauthor) letter see Tannenbaum, Rennee P., 699
Korman, Nancy E. (author) letter, notice of textbook errors, 354
Kowarski, A. (coauthor) see Kowarski, C.R., 409
Kowarski, C.R. (coauthor) The Constant Blood Withdrawal Method for the Area Under the Plasma Concentration Curve, 409
Kuhn, John G. (coauthor) see Fischer, Richard G., 767

L

Labeling, bureau of ATF, 477; food, more information, 636; symbolic directions on prescription labels, 588
Labelatol, hemodynamic effects (ab) 455; rate of onset after oral dosing (ab) 456
Laetrite, insurance coverage, 309; U.S. Supreme Court decision, 556

Lamy, P.P. (coauthor) see Powell, M.F., 506
Lasagna, Louis (author) The Uncertain Future of Drug Development, 192; on role of academic clinical pharmacologist, 275
Latini, R. (coauthor) letter see Tognini, G., 452
Lead, FDA program for reducing amount in food, 801
Leclithin, in psychiatry (CTF) 540
Leibowitz, Alan (coauthor) see Gee, Joseph P., 567
Leland, Mickey, testimony on saccharin, 557; on the Hill, member subcommittee, 474; VIP in the news, 477
Leong, Linda (coauthor) DIAS Rounds, methylphenidate rhabdomyolysis, 161
Letters to the Editor, advising the patient, 110; aminoglycoside antibiotics, dosing adjustments of, 44; antiplatelet drugs: comments, 451; availability of phenytoin infusion concentrate, 783; benzodiazepine use in glaucoma, 109; cimetidine ad nauseam?, 354; cimetidine, possible overutilization of, 43; cimetidine, possible overutilization of, another viewpoint, 354; cimetidine treatment of pruritus, 611; clarification of article on antiplatelet drugs, 451; clinical practice in Riyadh, 781; comments on constant blood withdrawal method for obtaining AUC, 781; authors' response, 782; computer system for monitoring patient medications, 166; concern for Drugdex cost, 783; correction of errors in programmable calculator article, 781; creatinine V_D biological half-lives of creatinine in normal adults with different ages, 110, authors' reply, 111; critique of critic's book review, 450, reviewer's response, 450; dantrolene in malignant hyperthermia, 297; dex-amethasone for respiratory distress, 526; digitalis preparations, questions and answers on use of, 700; disopyramide induced agranulocytosis, 165; drug compliance, comment on, 528; drug indications, non-FDA approved, 109; drug therapy in nursing homes, comment, 298; 5-fluorocytosine, error in article, 698; generic prescribing, letter to ABC-TV program, 699; hepatotoxicity possibly associated with erythromycin ethylsuccinate, 236; hospital pharmacy survey, 357; identification on diazepam precipitate, 612; judicial views article, comments on, 451; L-tryptophan in psychiatric practice — another possible indication, 782; author's response, 782; Maryland hospital pharmacy seminar, 238; more on "why not more pharmacists," 298, authors' reply, 298; morphine iv infusion for chronic pain, 297; necessity for faculty coauthorship questioned, 528; news not fit to print, 110; new zinc salt in dermatology, 611; notice of textbook errors, 354; oxtriphylline for A-B spells in the newborn, 238; Paget's disease: cost of therapy, 111; paraquat contaminated marijuana, 43; percent saturation of an enzyme system, 47; authors' reply, 47; Pharm.D. debate, comments on, 110; phenytoin crystallization, the effect of sodium hydroxide on, 139; phenytoin 300 mg daily, criticism of article, 167, authors' response, 168; physical assessment articles praised, 166; pediatric medicine, 453, authors' response, 453; pediatric medicine clarified, 452; possible E.E.S.-induced hepatotoxic reaction, 612; PPI readability, 355; prazosin, action of, de-fied, 527, authors' reply, 527; prazosin, more on, 527, authors' reply, 528; problems with metrication, 611; propriety of reviewing review articles, 357, authors' reply, 357; readers comment on French abstracts, 698; renacidin irrigation, 165; serum drug level usage review—a clinical pharmacy service, 44; survey of written drug information, 699; therapeutic drug monitoring meeting, 452; tobramycin, gentamicin and thrombocytopenia, 238; University of Toledo pharmacy seminar, 529
Levamisole, in infectious disease (CTF) 788; in recurrent herpes simplex labialis (ab) 551
Levy, Gerhard (author) book review, 531
Leward, R.S. (coauthor) letter, clinical practice in Riyadh, 781
Lice, see Pediculosis
Lidocaine, compared to amiodarone (DIAS Rounds) 397; in toxicology (CTF) 541; intraarterially in angiography (DIAS Rounds) 596
Lien, Eric J. (author) letter, pKa values, 610
Lignocaine, pharmacokinetics (ab) 58
Liguori, Salvatore (author) letter, PPI readability, authors' response, 356
Lindane, see Gamma Benzene Hexachloride
Liothyronine, effect in L-tryptophan, 393
Liskow, Barry I. (coauthor) see Richards, Mark L., 336
Literature (column) 50, 115, 170, 239, 301, 364, 530, 613, 784; indexing and abstracting systems, 513
Lithium, compared with imipramine, 405; dose-related side effects, 493; effect in mania, 405; in anesthesiology (CTF) 539; increase in urinary VMA excretion (DIAS Rounds) 262; monitoring therapy in manic-depressive illness, 492; non-dose related side effects, 494; pharmacokinetics, 407; prevention of corticotropin-induced psychosis (ab) 553
Little, Forbes (coauthor) see Luckman, Roger, 136
Liver Tumors, and oral contraceptive therapy, 680, 741
Longe, R. Leon (coauthor) Physical Assessment of the Neck and its Related Structures, 644
Lott, Rex S. (coauthor) letter, creatinine V_D biological half-lives of creatinine in normal adults with different ages, authors' reply, 111
Loughner, John (author) letter, Paget's disease: cost of therapy, 111
L-tryptophan, in psychiatric practice (letter) 782
Luckman, Roger (coauthor) Drug Compliance — A Study of Patient Behavior Based on Medical Records, 136
Lugol's Solution, for hyperthyroidism, 652
Lukasiewicz, Ronald H. (author) book review, 52
Lung Cancer, fallacy of the five year survival, 472

Luteinizing Hormone, in obstetrics/gynecology (CTF) 706

M

MacLeod, S. M. (coauthor) Parenteral 5-Fluorocytosine for Candidiasis, 72
Malathion, in pediculosis treatment (DIAS Rounds) 398
Malpractice, summons, North Carolina case, 475
Mania, lithium therapy, 405; tryptophan treatment, 394
Manufacturers, see also Pharmaceutical Industry; help for small-volume, 636
Marijuana, and health, 555; paraquat and pulmonary damage (letter) 43
Marshall, James H. (coauthor) see Small, Ralph E., 286
Martz, Robert C. (coauthor) letter, dantrolene in malignant hyperthermia, 297
Massachusetts, list of interchangeable drugs, 476
Massoud, Neil (coauthor) A Way of Decreasing Medications in a Community Hospital, 266
Matut, Robert J. (coauthor) letter, error in 5-fluorocytosine article, 698
McCoey, Linda (author) book review, 533
McGraw, Benjamin F. (coauthor) case report, topical corticosteroid-induced cataracts, 537
McKenney, James M. (author) book review, 117
McLeod, Donald C. (author) letter necessity for faculty coauthorship questioned, authors' reply, 529; (coauthor) see Gee, Joseph P., 567; (ed) A Health Priority: Continued Innovation in Pharmaceutical Industry and Practice, 691; (ed) Board Certification in Clinical Pharmacology: Bane or Boon?, 524; (ed) Donald E. Franke and Clinical Pharmacy, 163; (ed) Future Direction of Drug Intelligence and Clinical Pharmacy, 233; (ed) The European Society of Clinical Pharmacy, 691
Measles, see Rubella
Medicaid, codes to errors in outpatient prescriptions, 474; merge staff with Medicare, 476
Medical Education, failure to include drug cost information, 157
Medicare, merge staff with Medicaid, 476
Medication Errors, see Errors, Medication
Mefenamic Acid, in obstetrics/gynecology (CTF) 540
Mercury, vapor lamps, ultraviolet radiation hazard, 800
Methazolamide, treatment of hypokalemic periodic paralysis, 326
Methicillin, penetration into bone and synovial tissue (ab) 174; treatment of S. aureus endocarditis, 150
Methimazole, for hyperthyroidism, 652
Methoxsalen, in cardiovascular disease (CTF) 787; effect of food on kinetics (ab) 551
Methyldopa, in pediatric hypertension, 657; interference with catecholamine measurements (DIAS Rounds) 262
Methylphenidate, abuse leading to rhabdomyolysis symptoms (case study) 161
Methylprednisolone, in urology (CTF) 789
Metoclopramide, pharmacokinetics and concentration effects (ab) 362
Metoprolol, drug evaluation data, 320; for angina pectoris (ab) 550; in ophthalmology (CTF) 624
Metrication, problems (letter) 611; (editorial) 376
Metrimazole, and antiemetics (DIAS Rounds) 262
Metronidazole, in infectious disease (CTF) 788; interaction with warfarin (ab) 553
Miconazole, in infectious disease (CTF) 624, 706; for oral candidiasis, 489
Milewski, Bob (coauthor) see Watson, Ronald, 609
Milk of Magnesia, in anesthesiology (CTF) 539
Miller, Bryce T. (coauthor) see Wartak, Joseph, 100
Miller, Jon R. (coauthor) see Hood, Jerry C., 774
Minaxalone, in anesthesiology (CTF) 623
Minocycline, black thyroid (DIAS Rounds) 261; for gonorrhea prophylaxis (ab) 550; in dermatology (CTF) 623; in infectious disease (CTF) 438
Minoxidil, in pediatric hypertension, 659
Modified Neurotoxin (MNT), for amyotrophic lateral sclerosis, 558
Monif, Gilles R.G. (coauthor) see Pomerance, Alan J., 348
Monitoring Drug Therapy, see Drug Therapy Monitoring
Monomelic Oxidase Inhibitor, response increased with tryptophan, 392
Mono-peptanin, in gastroenterology (CTF) 623
Morphine, iv infusion for chronic pain (letter) 297
Morrison, Barbara J. (author) Prazosin Hydrochloride, 212
Mosko, Paul J. (author) letter, L-tryptophan in psychiatric practice — another possible indication, 782
Moskol, Fredric E. (coauthor) see Beasley, John W., 351
Mungall, Dennis (coauthor) see Stewart, Clinton, 692
Murphy, Kelly J. (co-author) Current Therapeutic Findings, 437, 539, 623, 705, 787
Murphy, John (coauthor) letter, necessity for faculty coauthorship questioned, 528
Mutchie, Kelly D. (coauthor) see Bosso, John A., 653
Mycosis, fluorocytosine treatment, 72
Myelography, antiemetics in (DIAS Rounds) 262
Myocardial Infarction, alprenolol and practolol for post-MI use (ab) 57

N

Nabilone, in oncology (CTF) 439
Nadolol, in hypertension (ab) 552
Nabata, M. (author) Sulindac (New Drug Evaluation) 736

- Naloxone, in toxicology (CTF) 440
- Nappi, Jean M. (author) letter, drug therapy in nursing homes, 298
- Naproxen, alternative to aspirin, 673; in obstetrics/gynecology (CTF) 624; in rheumatology (CTF) 439; pharmacokinetics, 674
- National Drug Education Foundation, 159
- National Health Insurance, and the 96th Congress, 475
- National Institutes of Health, role in research funding, 192
- National Science Foundation, role in research funding, 192
- Neck, physical assessment, 644
- Nefopam, compared with aspirin (ab) 174
- Nesbitt, Lloyd (author) letter, pediatric medicine, 453
- Neomycin Sulfate, in cardiovascular disease (CTF) 787
- Netilmicin, pharmacokinetics (ab) 119, in newborns (ab) 456, (ab) 552
- Neurology (CTF) bromocriptine, 540, 706; clonidine, 788; clorazepate, 439; dexamethasone, 788; isoproterenol, 540; phenytoin, 439; plasma exchange, 788; protriptyline, 788; thiopropazate, 706; tolifenamide, 706; valproate sodium, 540
- Neurosyphilis, treatment of (case study) 160
- Nialamide, with L-tryptophan, 392
- Nicolau's Syndrome, benzathine penicillin (case report) 443; treatment with heparin and streptokinase (case report) 443
- Nicotinamide, effect on L-tryptophan, 393
- Nitrites, update, 557
- Nitrofurantoin, childhood UTI (ab) 57
- Nitroglycerin, cigarettes (ab) 294; for IV infusion, 14; in intravenous therapy (CTF) 540; ointment, response (CTF) 705; preparation of iv, 14
- Nitroprusside, compared to dobutamine, 728; in cardiovascular disease (CTF) 705; in pediatrics (CTF) 624; in pediatric hypertension, 661
- Nitrosamines, in alcoholic beverages, 717
- Noninfectious, in psychiatry (CTF) 541
- Noncompliance, see Patient Compliance
- Nursing, pharmacology course by a hospital pharmacist, 664
- Nutrition (CTF), diet, 788
- Nystatin, for oral candidiasis, 589
- O**
- O'Brien, Donald R. (author) letter, Maryland hospital pharmacy seminar, 238
- Obstetrics/Gynecology (CTF) antibiotics, 788; breast feeding, 706; bromocriptine, 439; clomiphene, 706; dextran, 439; disopyramide, 540; luteinizing hormone, 706; mefenamic acid, 540; valproic acid, 439
- Occupational Safety and Health Administration, basis for identifying possible carcinogens, 373
- Office of Disease Prevention and Health Promotion, 384
- Office of Technological Assessment, 159
- Oguzwala, C. Dwayne (author) book review, 117
- Oncology (CTF) antibiotics, 706; cyclophosphamide, 540; cytosine arabinoside, 788; estrogens, 706; fluorouracil, 439; nabifone, 439; smallpox vaccination, 706; tamoxifen, 540; treatment of testicular cancer, 706; vitamin C, 788
- Ontario Prescriptions at Reasonable Cost (PARCOST) 157
- Ophthalmology (CTF) beta-adrenergic blocking agents, 540; cycloplegics, 439; isoproterenol, 439; silicone oil, 540; timolol, 439
- Orabase[®], for intraoral aphthous, 490
- Oral Contraceptives, benign liver tumors, 680; case study of benign liver tumors, 741
- OTC Weight Control Products, FDA panel reviews, 557
- Ott, Franklin, B. (coauthor) see Greenlaw, Cal W., 150
- Overregulation, see Regulation
- Owen, John A. (ed) Introducing USP Update, 523
- Oxalindin, penetration into bone and synovial tissue (ab) 174
- Oxandrolone, in endocrinology (CTF) 438
- Oxprenolol, bioavailability (ab) 457; compared to propranolol in essential hypertension (ab) 362; for angina pectoris (ab) 550
- Oxtriphyline, for A-B spells in newborns (letter) 238
- Oxyphenbutazone, compared to sulindac, 736
- P**
- Package Inserts see Patient Package Inserts
- Packaging, Unit-of-Use, a discussion (ed) 376; FDA update seminar, 473; update (ed) 402
- Paget Sound Group Health Cooperative, drug price information to physicians, 158
- Paget's Disease, therapy cost (letter) 111
- Pain, morphine iv infusion (letter) 297
- Pakes, Gary E. (author) case report, neuroleptic withdrawal and vomiting, 350; (author) L-tryptophan in Psychiatric Practice, 391; response to letter, 783
- Pancreatic Enzymes, in gastroenterology (CTF) 539
- Panush, Richard S. (coauthor) see Delafuente, Jeffrey C., 385
- Papaverine, new drug status, 558
- Paracetamol, hepatic necrosis (ab) 359
- Paracetamol, assumptions, 519; for statistical inference, 518
- Paraquat, marijuana contamination (letter) 43
- Park, Glen D. (coauthor) Dobutamine: A New Agent for the Management of Cardiac Decompensation, 728
- Parkinsonism, antipsychotic drugs, 204
- Pathak, Dev S. (editor) Research Methodology, 441, 518
- Patient Compliance, and drug cost (letter) 526, author's response, 526; and patient counseling in diabetics, 506; a study, 136; effect of patient package inserts, 423; in diabetes therapy, 141; in hypertension therapy, 141, 471; in URIs, 141; in UTIs, 141; recommendations to improve, 143
- Patient Counseling see Pharmacist Consultation; Clinical Pharmacy
- Patient Labeling, see also Patient Package Inserts; feasibility of symbolic directions on prescription labels, 588; new requirements, 635
- Patient Monitoring see Drug Therapy Monitoring
- Patient Package Inserts (PPIs), changes on estrogens, 558; Chicago hearings, 717; FDA proposal, Sept-ctr-1 informing of possible adverse drug effects, 423; officially proposed by FDA, 565; readability (letter) 355, author's response, 356; USPC critical of FDA regulation, Nov-ctr 1; USPC qualifications for their preparation (ed) 523
- Patterson, Herb (coauthor) see Self, Timothy H., 96
- Pediatrics, and hypertension, 653, WHO's concern for health of children, 627
- Pediatrics (CTF) azulfidine, 439; cholestyramine, 540; diazepam, 439; domperidone, 540; glucose, 439; in domipach, 706; 1,25-dihydroxycholecalciferol, 540; phenobarbital, 706; pneumococcal vaccine, 540; theophylline, 540, 788; total parenteral nutrition, 439; valproate sodium, 706; vitamin E, 439, 788
- Pediculosis, treatment of, (DIAS Rounds) 398
- Penicillin, G crystalline, SBE prophylaxis, 489; neurosyphilis treatment (DIAS Rounds) 160; pharmacokinetics in gonococcal urethritis (ab) 551; treatment of S. aureus endocarditis, 150; utilization with clindamycin (case report) 349; penicillin VK, SBE prophylaxis, 489
- Perry, Paul J. (coauthor) see Richards, Mark L., 336
- Perspectives in Clinical Pharmacy, role of clinical pharmacist (quote from book) 273
- Pertussis, immunization, 389
- Peterson, Carl W. (author) letter, possible overutilization of cimetidine-another viewpoint, 354
- Peterson, Robert G. (coauthor) see Grabert, Brian, 778
- PharmACE[™] 79 Test Questions, 9, 123, 177, 246, 305, 371, 465, 543, 629, 709, 796
- Pharmaceutical Education see Doctor of Pharmacy
- Pharmaceutical Industry, drug poisoning information, 471
- Pharmacist Consultation, beclomethasone dipropionate aerosol, 767; in dentistry practice, 487; in diabetes, 506; letter(s), 110
- Pharmacist's Roles, see also Pharmacist Consultation; and Clinical Pharmacy; as instructor, 664; consultant vs. dispensing, 554; dental treatment protocols, 486; physical assessment, 644; quote from *Perspectives in Clinical Pharmacy*, 273; with infection control (ed) 638
- Pharmacokinetics, amoxicillin (ab) 362; ampicillin, iv in children (ab) 551; cefamandole (ab) 456, in infants (ab) 550; chloramphenicol (ab) 551; cinoxacin (ab) 457; constant blood withdrawal method for area under the curve, 409; dobutamine (ab) 174, 728; doxapram (ab) 363; furosemide, 655; hand-held calculator as clinical tool, in 328; hydrochlorothiazide, 655; insulin, 573; lithium, 407, 492; L-tryptophan, 391; metoprolol (ab) 362; monitoring phenytoin therapy in a pregnant epileptic (case report) 534; naproxen, 674; netilmicin (ab) 456; in newborns (ab) 552; oral anticoagulants (ab) 552; penicillin in gonococcal urethritis (ab) 551; piperacillin (ab) 294; propranolol (CTF) 438, in the elderly (ab) 294; pulmonary disease (ab) 58, 59; student goals, 274; sulindac, 736; tobramycin (case report) 693; trimethoprim-sulfamethoxazole (ab) 458
- Pharmacology, nursing course outline, 665
- Pharmacy Education, increase in number of pharmacists (letters) 235; role of Pharm.D., 273
- Pharmacy Practice see also Pharmacist Consultation; Pharmaceutical Education; good manufacturing practice and good dispensing practice (ed) 802; pharmacists' participation on rounds (letter) 781
- Pharmacy Services, see Clinical Pharmacy; Pharmacy Practice
- Pharm.D. see Doctor of Pharmacy
- Phenazopyridine, in toxicology (CTF) 789
- Phencyclidine, induced psychosis (case study) 337; in toxicology (CTF) 541, (CTF) 789
- Phenelzine, acetylator phenotype of recipient (ab) 121; with L-tryptophan, 392
- Phenformin, current FDA status, 375
- Phenobarbital, decreased clearance caused by chloramphenicol (ab) 171; in pediatrics (CTF) 706
- Phenothiazines, adverse reactions, 198; as adjunct to lithium therapy, 407; convulsions (DIAS Rounds) 263; use in PCP intoxication, 338; withdrawal symptomatology (case study) 350
- Phentolamine, in cardiovascular disease (CTF) 438
- Phenybutazone, compared to sulindac, 736; interaction with warfarin (ab) 553
- Phenyltoloxamine, overdose (case report) 446
- Phenytoin, availability of an infusion concentrate, 783; compared to amiodarone (DIAS Rounds) 397; decreased clearance caused by chloramphenicol (ab) 171; dosage, discussion (letter) 167, author's response, 168; effect on albumin-bilirubin binding, 500; effect of sodium hydroxide on precipitation (letter) 169; increased requirement during pregnancy (case report) 536; in neurology (CTF) 439; interaction with chloramphenicol (case report) 609; rate of accumulation (ab) 363; saturation of enzyme system (letter) 47
- Phlebotomy, drug interference with evaluation (DIAS Rounds) 261; use of alpha-MPT (DIAS Rounds) 596
- Phillips, Thomas G. (author) letter, action of prazosin clarified, 527
- Phosphates, valence and methods of quantification in parenteral solutions, 579
- Physical Assessment, neck, 644
- Physicians, and an expanded role for the community pharmacist, 353; appreciation of adverse drug effects, 423; clinical pharmacology as a board specialty (ed) 524; effect of price information on prescribing patterns, 156; need to answer malpractice summons, 475; patient education and antibiotic compliance, 142; physician glut and its implications for clinical pharmacy (ed) 448
- Physostigmine, in neurology (CTF) 624
- Pierpaoli, Paul G. (ed) The Physician Glut—What Does It Portend for Clinical Pharmacy?, 448
- Pietrusko, Robert G. (author) book review, 785
- Pindolol, in cardiovascular disease (CTF) 787
- Piperacillin, enhances aminoglycoside antibiotics (ab) 119; in infectious disease (CTF) 624; pharmacokinetics (ab) 294
- Pipkin, Michael (coauthor) see Self, Timothy H., 96
- Piriou, Alain (coauthor) letter see Reiss, Daniel, 610
- pKa Values (letter) 610
- Plasma Exchange, in neurology (CTF) 788
- Platelets, aggregation, effect of propranolol-aspirin therapy (ab) 549; antiplatelet drugs, 81; role in thrombus formation, 78
- Pneumococcal Vaccine, in pediatrics (CTF) 540
- Pneumonia, clindamycin (ab) 458
- Podiatric Medicine, clarification (letter) 452, (letter) 453, author's response, 453
- Poison Information, availability from pharmaceutical industry, 471
- Poisoning, see Adverse Drug Reactions
- Polack, A. E. (author) Some Perspectives on U.S. Pharmacy, 209
- Pomerance, Alan J. (coauthor) case report, anaphylactic reaction with parenteral clindamycin, 348
- Potassium Chloride, health aspect as food ingredient, 800
- Potassium Iodide, as blocking agent in radiation exposure (ed) 478; patient information, 479
- Potter, S. Kip (coauthor) DIAS Rounds, amiodarone in ventricular arrhythmia, 397
- Povidone-Iodine, in infectious disease (CTF) 438
- Powell, M. F. (coauthor) Diabetic Patient Compliance as a Function of Patient Counseling, 506
- Practolol, after myocardial infarction (ab) 57; for angina pectoris (ab) 550
- Prazosin, cardiac output, 212; discussion of first-dose phenomenon (letter) 527, author's response, 527; first-dose phenomenon (case report) 444; in pediatric hypertension, 658; in cardiovascular disease (CTF) 705; use in chronic congestive heart failure (letter) 527, author's response, 528
- Prednisone, in rheumatology (CTF) 541
- Pregnancy, effect of lithium, 494
- Pregnancy Prevention and Care Act of 1978, 383
- Prescribing, cost effect 156; generic (letter) 699
- Preventive Medicine, Surgeon General's goals, 383
- Price Information see Cost
- Probenecid, effects on furosemide (ab) 171; Improves response to indomethacin (ab) 172; with piperacillin (ab) 294
- Procainamide, compared to amiodarone (DIAS Rounds) 397
- Prochlorperazine, compared to trimethobenzamide (DIAS Rounds) 263
- Progestins see Oral Contraceptives
- Propoxyphene, FDA update, 556
- Propranolol, compared to oxprenolol in essential hypertension (ab) 362; for angina pectoris (ab) 550; in cardiovascular disease (CTF) 438; in general medicine (CTF) 788; in pediatric hypertension, 656; in pediatrics (CTF) 624; pharmacokinetics (CTF) 438, in the elderly (ab) 294; platelet anti-aggregating properties (ab) 549; treatment of hypokalemic periodic paralysis, 326
- Propylthiouracil, antithyroid action (DIAS Rounds) 261; for hyperthyroidism, 652
- Prostaglandin F₂ alpha, in obstetrics/gynecology (CTF) 624
- Protriptyline, in neurology (CTF) 788
- Provost, George P. (ed) In Memoriam: Donald E. Francke, 163
- Pruritis, treatment with cimetidine (ab) 295, (letter) 611
- Pseudomembranous Colitis, clindamycin-induced (DIAS Rounds) 39; vancomycin for antibiotic-associated disease (DIAS Rounds) 39; (ab) 57
- Psychiatry (CTF) amitriptyline, 706; amobarbital, 540; clozapine, 540; conjugated estrogens, 439; desipramine, 439; dihydroergotamine, 706; haloperidol, 788; imipramine, 706; lecitin, 540; nomifensine, 541
- Psychotherapeutic Agents, adverse reactions, mechanisms, and treatment, 198
- Public Health Service see United States Public Health Service
- Pulliam, Charles C. (coauthor) see Solomon, David K., 669
- Pulmonary Disease, drug kinetics (ab) 58; (CTF) atropine sulfate, 541; chlorpheniramine, 788; cimetidine, 788; quinacrine, 788; terbutaline, 439; tobramycin, 541
- Purdue University, recipient of HEW grant, 799
- Pyrazinamide, second-line antituberculosis therapy, 433
- Pyridoxine, rheumatoid arthritis (DIAS Rounds) 38; with L-tryptophan, 393
- Pyrogen Testing, limulus test, rabbit test, 16
- Q**
- Quinacrine, in pulmonary disease (CTF) 789
- Quinidine, compared to amiodarone (DIAS Rounds)

397; digoxin interaction (case study) 286; dosage (ab) 457
 Quinn, Suzanne L. (coauthor) letter, see Murphy, John, 528

R

Radiation, hazard of mercury vapor lamps, 800
Rapp, Robert P. (coauthor) see Canafax, Daniel M., 534; (author) book review 50, 240; (coauthor) letter, criticism of phenytoin 300 mg daily article, authors' response, 168; (coauthor) letter, percent saturation of an enzyme system, authors' reply, 47
Rawlings, John L., ASCP George F. Archambault Award, 717
Raymond, Glynn (coauthor) letter, identification of injectable diazepam precipitate, 612
Red Blood Cells, determining lithium levels, 493
Red Dye No. 2, current FDA status, 375
Red Dye No. 4, current FDA status, 375
Regulation, Bumpers Amendment, 799
Reiss, Daniel (coauthor) letter, new zinc salt in dermatology, 611
Reith, H. (author) letter, availability of phenytoin infusion concentrate, 781
Renacidin, in kidney irrigation (letter) 165
Renal Calculi, use of renacidin, 165
Renal Failure, dosage adjustment, 269
Research, biomedical and behavioral, HEW plan, 717; clinical pharmacy needs, 669
Research Methodology, parametric or non-parametric statistics, part 1, 441; part II, 518
Reserpine, in pediatric hypertension, 657
Respiratory Distress Syndrome, prevention (DIAS Rounds) 160
Rhabdomyolysis, amphetamine abuse (DIAS Rounds) 161
Rheumatoid Arthritis, treatment with pyridoxine (DIAS Rounds) 38
Rheumatology (CTF) N-acetylcysteine, 789; aspirin, 789; naproxen, 439; prednisone, 541
Richards, Mark L. (coauthor) Phencyclidine Psychosis, 336
Richmond, Julius B. (author) Health Care 'n America Takes A New Direction, 383
Riddiough, Michael A. (coauthor) see Solomon, David K., 669
Rifampin, in infectious disease (CTF) 439; in pulmonary disease (CTF) 625; tuberculosis therapy, 433
Robuto, Stephen M. (coauthor) letter see Galinsky, Raymond E., 781
Rollins, C. Larry (coauthor) see McGraw, Benjamin F., 537
Rotblatt, Michael (coauthor) DIAS Rounds, Capmul 8210, 399
Royal Drug Case, anti-trust violation, 309
Rubella, immunization, 389
Rubinstein, Elan (coauthor) DIAS Rounds, glucocorticoids in the treatment of respiratory distress syndrome, 160
Rumack, Barry H. (coauthor) see Conner, Christopher S., 86; (coauthor) see Grabert, Brian, 778
Ryll, Chuck (coauthor) DIAS Rounds, warfarin-disopyramide interaction, 260

S

Saccharin, testimony, 557
Salbutamol, asthma (ab) 58
Salem, Ronald B. (author) letter, the effect of sodium hydroxide on phenytoin crystallization, 169
Salicylate see Aspirin
Saliva, drug concentration in (ab) 174; lithium levels, 493
Sandler, Alan I. (coauthor) see Ward, John W., 14
Sandow, Neil L. (coauthor) DIAS Rounds, treatment of neurosyphilis, 160
Saputo, Vincenzo (coauthor) case report, Nicolau's syndrome from benzathine penicillin, 443
Schizophrenia, L-tryptophan, 394
Schneeweiss, Fred (author) Alternative Sources of Drug Information, 512; (author) letter, why not more pharmacists?, 235
Schultz, David W. (coauthor) case report, hypercalcemia secondary to Tums®, 350
Sciarras, John J. (coauthor) letter see Bartilucci, Andrew J., 298
Sedation, antipsychotic drugs, 202
Seizures, see Epilepsy
Self, Timothy H. (coauthor) Clinical Pharmacy Service—contributions on a Part-time Basis, 282; (coauthor) Intravenous Ethchlorvynol-Induced Pulmonary Edema, 96
Sellers, E. M. (coauthor) see MacLeod, S.M., 72
Sensitization, investigational drug information, 342
Shimomura, Sam K. (coauthor) DIAS Rounds see King, Christine, 39; Leong, Linda, 161; Gephart, William K., 262; Rotblatt, Michael, 399; (editor) DIAS Rounds, 38, 160, 260, 397, 596
SIADH, adenine arabinoside (ab) 293
Silicone Oil, in ophthalmology (CTF) 540
Singer, Walter (coauthor) letter see Bartilucci, Andrew J., 298
Sisac, Thomas S. (author) book review, 614; (coauthor) see Solomon, David K., 669
Small, Ralph E. (coauthor) Quinidine-Digoxin Interaction, 286
Smallpox Vaccination, in oncology (CTF) 706
Smith, Gary H. (coauthor) see Ivey, Marianne F., 603
Smoking, relation to health, 471
Sodium Chloride, health aspect as food ingredient, 800
Sodium Hydroxide, effect on phenytoin crystallization, 169

Sohn, C.A. (coauthor) letter see Tannenbaum, Renee P., 699
Solomon, David K. (coauthor) Research in Clinical Pharmacy: Needs and Priorities, 669
Spiroolactone, adverse reactions (ab) 118; in pediatric hypertension, 656
Spivey, Richard N. (author) letter, propriety of reviewing review articles, 357
SSK1 see Potassium Iodide
Staphylococcus aureus, endocarditis, methicillin-resistant (case study) 152
Statistics, parametric or nonparametric, part I, 441; part II, 518
Stein, Stanley I. (author) letter, possible E.E.S.-induced hepatotoxic reaction, 612
Stein, Z.L.G. (author) case report, prazosin and the "first-dose phenomenon," 444
Steroids see also Individual Drug Names; Oral Contraceptives; and cataract formation (case report) 538; prevention of respiratory distress syndrome (DIAS Rounds) 161
Stewart, Clinton (coauthor) case report, ethyma gangrenosum, 692; (coauthor) letter, disopyramide induced agranulocytosis, 165
Stewart, Ronald B. (coauthor) see Harper, J. Michael, 425; (author) book review, 784
Stetley, Stephen N. (coauthor) letter see Greenlaw, Cal W., 236
Streptokinase, in cardiovascular disease (CTF) 787; treatment of Nicolau's syndrome (case report) 443
Streptomycin, tuberculosis therapy, 432
Subacute Bacterial Endocarditis, treatment protocol, 488
Sulfadiazine, bioavailability (ab) 362
Sulfapyrazole, as antiplatelet agent, 80; in threatened TIA (ab) 56
Sulindac, aspirin alternative, 675; compared to aspirin, 736; pharmacokinetics, 736
Sulphonylurea, effect on plasma cholesterol levels in diabetics (ab) 119
Sunset Laws, updating licensing boards, 717
Sutarjono, K. (author) letter, pediatric medicine, author's response, 453; (author) letter, comments on Pharm.D. debate, 110
Sutton's Lesions, treatment protocol, 490

T

Taketomo, Robert (coauthor) letter see Floyd, Ronald A., 45
Tamoxifen, in oncology (CTF) 540
Tannenbaum, Renee P. (coauthor) letter, generic prescribing: an open letter to ABC-TV program, 699
Tardive Dyskinesia, antipsychotic drugs, 206; treatment, 206
Tartrazine, new label information, 556
Taubman, Albert H. (coauthor) see Luckman, Roger, 136; (author) letter, comment on drug compliance, authors' reply, 526
Taylor, A. Thomas (coauthor) see Longe, R. Leon, 644
Teaching Methods, nursing pharmacology course, 664
Teratogenesis, Bendectin®, 800; effect of lithium, 494
Terbutaline, in pulmonary disease (CTF) 439
Tetanus, immunization, 388
Tetracycline, neurosyphilis treatment (DIAS Rounds) 160; oral rinses for intraoral aphthous, 490
Theophylline, absorption affected by product formulation (ab) 173; asthma treatment (ab) 173; charcoal inhibition of absorption (ab) 553; effect on albumin-bilirubin binding, 500; in pediatrics (CTF) 540, 788; use in premature apnea, 27
Thermoregulation, antipsychotic drugs, 200
Thiazides see Individual Drug Names
Thiopropazate, in neurology (CTF) 706
Thioridazine, withdrawal symptomatology (case report) 350
Third Party Payment, reducing hospital drug usage, 266
Thompson, Dennis (coauthor) letter, concern for Drugdex cost, 781
Three-Mile Island Nuclear Crisis, pharmacy involvement (ed) 478
Thromboembolism see Platelets
Thrombus Formation see Platelets
Thyroid Gland, black thyroid and minocycline (DIAS Rounds) 261
Ti, T.Y. (coauthor) see MacLeod, S.M., 72
TiAs, antiplatelet drugs, 80; aspirin (ab) 56; sulfipyrazole (ab) 56
Ticarcillin, ethyma gangrenosum, 694; enhance aminoglycoside antibiotics (ab) 119
Ticrynafen, in cardiovascular disease (CTF) 438, 623
Timolol, in ophthalmology (CTF) 439; pharmacologic observations (ab) 172
Tobacco see Smoking
Tobramycin, ethyma gangrenosum, 694; in pulmonary disease (CTF) 541
Tognoni, G. (coauthor) letter, therapeutic drug monitoring meeting, 452
Tolamolol, for angina pectoris (ab) 550
Tolazoline, treatment of clonidine overdose, 778
Tolfenamic Acid, in neurology (CTF) 706
Tolmetin, aspirin alternative, 675
Total Parenteral Nutrition see Hyperalimentation
Toxicity see Adverse Drug Reactions; Individual Drug Names
Toxic Epidermal Necrolysis, allopurinol induced, 219
Toxicology (CTF) amantadine, 541; caustic agents, 625; diazepam, 625; ethylene oxide, 625; haloperidol, 789; human diploid vaccine, 440; lidocaine, 541; naloxone, 440; phencyclidine, 541, 789; phenazopyridine, 789
Tranylepromine, increased response with L-tryptophan, 392
Travis, Patricia (coauthor) letter see Leward R.S., 781

Treponema pallidum, neurosyphilis (DIAS Rounds) 160
Tretinoin, in cardiovascular disease (CTF) 787; in dermatology (CTF) 539
Triamcinolone Acetonide, for intraoral aphthous, 490
Triamterene, in pediatric hypertension, 656
Tricyclic Antidepressants, and iatrogenic manic states, 404
Trimethobenzamide, compared to prochlorperazine (DIAS Rounds) 263
Trimethoprim-Sulfamethoxazole, pharmacokinetics (ab) 458
Trissel, Lawrence A. (coauthor) Investigational Drug Information, 340
Tryptophan, antidepressant, 392; biopharmaceutics and pharmacokinetics, 391; compared with amitriptyline, desipramine and clomipramine, 392; effect of liothyronine and nicotinamide, 393; for mania and schizophrenia, 393; with carbidopa, pyridoxine, and ascorbic acid, 393
Tuberculosis, pulmonary, multi-drug resistant (case study) 431; treatment with isoniazid, streptomycin, 432; rifampin, pyrazinamide, ethionamide, kanamycin, capreomycin, cycloserine, 433
Tucker, Stuart V. (coauthor) see Ward, John W., 14

UWV

Uges, Donald R. A. (author) letter, oxtriphylline for A-B spells in the newborn, 238
UK 14, 275, isotropic effect (ab) 57
Ulcers see Duodenal Ulcers
Unit Dose System see Drug Distribution Systems
Unit-of-Use Packaging see Packaging, Unit-of-Use
United States Pharmacopeia, dispensing information, advantages of a new text, 476; "first call" for 1980 quinquennial meeting, 308
United States Pharmacopeial Convention, announcement of USP Update (ed) 523; balloting for Revision Committee, Nov-ctr 4; Committee of Revision election, Sept-ctr 1; cooperation with the American Nurses' Association, 373; critical of PPI regulation, Nov-ctr 1; device reporting program expands to hospitals, Sept-ctr 2; drug information system, Sept-ctr 1; establish antibiotic monograph subcommittee with FDA, Sept-ctr 3; expand laboratory and reference standards facilities, Sept-ctr 2; Fifth Supplement announced, 474; public drug information (USP DI), Nov-ctr 1; purpose of USP update, Sept-ctr 4; quinquennial meeting (ed) 560; toll free number for drug product problems, Nov-ctr 4; USPC 1980 meeting plans, Sept-ctr 4; USPXX-NFXV contain more monographs, Sept-ctr 2
United States Public Health Service, chief pharmacy officer, 717; cosmetic surgery, 476; disease prevention, 384
United States Supreme Court, laetrile decision, 556
University of Toledo Pharmacy Seminar, announcement, 529
Urology (CTF) acetylcysteine, 440; allopurinol, 789; bendroflumethiazide, 541; diazepam, 440; diphosphonate, 440; hemodialysis, 625; imipramine, 440; methylprednisolone, 789
Ursodeoxycholic Acid, in gastroenterology (CTF) 787
Vaccination, active and passive agents used for immunization, 387
Valium® see Diazepam
Valproate Sodium see Valproic Acid
Valproic Acid, drug evaluation data, 18; hair loss, 597; in neurology (CTF) 540; in obstetrics/gynecology (CTF) 439; in pediatrics (CTF) 706
Vancomycin, in infectious disease (CTF) 706; microbial suppression in leukemias (ab) 457; SBE prophylaxis, 488; treatment of pseudomembranous colitis (DIAS Rounds) 39; treatment of *S. aureus* endocarditis, 150
Varicella-Zoster Virus, pathophysiology and treatment of infections, 255
Vasopressin, in gastroenterology (CTF) 787
Verapamil, in cardiovascular disease (CTF) 438, 705
Vidarabine, administration and toxicity, 257; in infectious disease (CTF) 439; SIADH (ab) 293; varicella-zoster infection, 255
VIPs, Bachrach, Clifford A., 559; Chambers, Robert K., 801; Coloclas, George H., 801; Coloff, Margery, 309; Deluca, John, 477; DeMarco, Carl T., 309; Engman, Lewis A., 559; Fischel, Robert P., 559; Forst, Helen V., 559; Gardner, Vincent R., 801; Goyan, Jere Edwin, 558, 801; Green, George B., 801; Hackett, Joseph J., 559; Harding, Roland F., 559; Kennedy, Donald, 477; Leland, Mickey, 477; Pilot, Larry, 477; Pollin, William, 477; Seife, Marvin, M.D., 559; Segal, Elliott, 309; Skolaut, Milton W., 559; Stetler, C. Joseph, 801; Timberlake, Captain Claude V., 801; Vodra, William, 309; Weaver, Lawrence C., 801; White, Eugene V., 309, 559; Zilz, David A., 801
Vitamin A, FDA evaluation, 800
Vitamin B₆, see Pyridoxine
Vitamin C see Ascorbic Acid
Vitamin E, in pediatrics (CTF) 439, 788
Vivian, Douglas (author) case report, three deaths due to hydrocodone in a resin-complex cough medicine, 445
Wagner, John G. (author) letter, percent saturation of an enzyme system, 47
Walker, John A. (coauthor) An Innovative Dental Pharmacy Practice, 486
Waller, Elaine (author) book review, 785
Ward, John W. (coauthor) Nitroglycerin For IV Infusion, 14
Warfarin, clinical pharmacokinetics (ab) 553; interaction with disopyramide (DIAS Rounds) 260
Warren, Betty L. (coauthor) Benign Liver Tumors and Oral Contraceptive Therapy, Part I, 680; Part II, 741

Warren, Duane E. (author) Antiplatelet Drugs, 78; (author) letter, propriety of reviewing review articles, authors' reply, 357

Wartak, Joseph (coauthor) Decision Tables for Planning Drug Therapy, 100

Washington News and Comments, 307, 373, 473, 554, 635, 717, 799

Watanabe, Arthur S. (author) book review, 54; (coauthor) see Conner, Christopher S., 86

Watanabe, Joyce C. (coauthor) DIAS Rounds, sodium valproate and hair loss, 597

Watson, Ronald (coauthor) case report, bleeding with continuous intravenous heparin infusion, 609

Webb, Jerry G. (author) book review, 784

Weisbuch, Jonathan B. (coauthor) see Luckman, Roger, 136

Weisman, Richard S. (coauthor) letter, dosing adjustments of aminoglycoside antibiotics, 44

Welker, Richard G. (coauthor) see Hart, Linda L., 414

Wells, Rhonda (coauthor) see Drew, John H., 498

Whitney, Harvey A.K., Jr. (ed) Asleep at the Switch, 232; (ed) Biomedical Journal Uniformity, Double Issue, and Other New Developments, 449; (ed) Pharmacy and Pharmacology: Importance of Collaboration at the Clinical Level, 296; (ed) The Creation of the American College of Clinical Pharmacy, 608; (ed) The Human Side of a Pharmacy Resident, 108; (ed) The Journal for Drug Therapy Decision Makers, 42; (ed) Unit-of-Use Packaging Will Eliminate the Last Vestige of the Old Era, 234

Whooping Cough see Pertussis

Williams, B.B. (coauthor) see MacLeod, S.M., 72

Withdrawal Reactions, see Adverse Drug Reactions

Wolff, Jay (coauthor) letter see Matutut, Robert, 698

World Health Organization, assessment of economic effects of adverse drug reactions, 423; concern for children's health, 627

XYZ

Xipamide, in cardiovascular disease (CTF) 705

Yost, Richard L. (coauthor) see Harper, J. Michael, 425; (coauthor) see Beck, Diane E., 572

Young, Byron (coauthor) authors' reply, see Rapp, Robert P., 47; (coauthor) authors' response, see Rapp, Robert P., 168

Zarowitz, Barbara J. (Morrison) (author) letter, action of prazosin clarified, authors' reply, 527; (author) letter, more on prazosin, authors' reply, 528

Zelmer, William A. (ed) Donald E. Francke, 164

Zelma, Robert N. (coauthor) The Effects of Price Information on Physician Prescribing Patterns - A Literature Review, 156

Zinc, contamination of iv solutions (ab) 56; in gastroenterology (CTF) 539; use in dermatology (letter) 611

ADVERTISERS

ADIS, Drug Treatment, Second Edition, O-ibc

American Pharmaceutical Association, APhA Drug Names, Ju-315; Computers for Pharmacy, Ja-46; Handbook of Nonprescription Drugs, N-711; Pharmacological and Biochemical Properties of Drug Substances, S-ibc

American Society of Hospital Pharmacists, Handbook of Drug Therapy, O-628

Burroughs Wellcome Company, Ascoclen-30, Ja-22, 23; Mr-154, 155; Septa DS Respiratory Indications, O-600-602; D-724-726; Septa DS Where the Action Is, Ja-5-8; F-67-69; Ap-188-190; Ma-252-254; JI-400-402

Drug Intelligence and Clinical Pharmacy, Inc., AID, O-621; N-708; D-816; Bound Volumes, F-127; Mr-184; Missing Copy Policy, S-482; PharmaCE 79, Ja-ibc; F-ibc; Mr-180; Ap-ibc; Ju-ibc; JI-468; PharmaCE 80, N-ibc; D-ibc; Pharmacokinetics '79 Seminar, Ja-17; Repertorio Terapeutico, 791; Reprints Available, Ja-54; F-128; Mr-169; Ap-223; Ma-279; S-544; Subscription Information, Ja-ibc; F-125; Mr-ibc; Ap-ibc; Ma-ibc; Ju-ibc; JI-ibc; S-529, ibc; O-ibc; N-ibc; D-813

Drug Intelligence Publications, Inc., Audio Courses, F-112, 113; O-599, 622; D-ibc; Biopharmaceutics and Pharmacokinetics, Ap-224; Containing Costs in Third Party Drug Programs, F-120; Dangerous Plants, Snakes, Arthropods and Marine Life, Toxicity and Treatment, F-105; JI-413; Diccionario de Especialidades Farmaceuticas, Ma-289; Drug Consultation Guide, Ja-62, 63; F-84, 85; Mr-182; Drug Interaction Chart, F-127; Ma-306; Fate of Drugs in the Organism, Ma-278; Fundamentals of Clinical Pharmacokinetics, S-542; D-773; Guide to Drug Information, S-ibc; Handbook for Counseling Patients on Their Medications, F-71; Mr-176; Ap-249; Ma-300; Handbook of Basic Pharmacokinetics, Ju-344; N-690; D-727; Handbook of Clinical Drug Data, Ja-55; F-126; Mr-216; Ap-216; JI-464; Handbook of the Pharmacology of Emergency Drugs for Paramedics, F-99; Mr-173; Ap-210; Ma-262; JI-413; Imprex, Ja-59; Mr-162; Ap-223; Ma-304; Ju-327; Index Nominum, Ja-28; Ap-231; Ju-314; Martindale The Extra Pharmacopoeia, F-122; Mr-ibc; Mediset, F-116; Mr-184; Ap-248; Multiple Book Ad, Ja-11; Mr-183; Ap-217; JI-469; O-599; D-ibc; Negwer, O-598; Organic Chemical Drugs and Their Synonyms, JI-429; Patient Counseling Aids, JI-424; S-533; N-714; Principles of Drug Information Services, Ja-41; F-ibc; Mr-131; Ap-191; JI-420; Problems in Pediatric Drug Therapy, O-ibc; N-ibc; D-ibc; USAN 1980, JI-399

Editio Cantor, Drug Research, Ja-45; Ju-343; JI-436; N-719; D-740

Eli Lilly and Company, "I think the response . . ." Ju-334, 335; Kefzol, Ap-230, 231; Ma-277, 278; Ju-313, 314; JI-459, 460; S-481, 482; O-566; D-735; "Our patient education . . ." JI-480, ibc; S-504, 505; O-623-633; "We've gained acceptance . . ." Ja-48, 49; F-76, 77; Mr-132, 133; Ap-242, 243; Ma-264, 265; "With specialized clinical training . . ." N-712, 713; D-792, 793

Elsevier/North Holland Inc., Multiple Book Ad, Ju-ibc; Pharmacy International, O-640; Trends in Pharmacological Sciences, F-114

Facts and Comparisons, O-618

Florida Society of Hospital Pharmacists, Annual Seminar, JI-462; S-482

George Washington University, Scanning Transmission Electron Microscopy, F-121

IVAC Corporation Volumetric Infusion Pump, Ap-insert between 216-217; Ma-ibc, 249; Ju-318-319; JI-ibc, 377; O-616-617

McGraw Laboratories, Accumed IV System, 790, 791

Merrell-National Laboratories, Medicine for Mankind, Ja-ibc; F-ibc; Mr-ibc

Personnel Placement, Ja-59; F-127; Mr-179, 181; Ap-240, 241, 248; Ma-303, 304; Ju-370; JI-460, 461, 462, 463; S-545, 546; O-631, 634; N-715, 716; D-794, 795

Philadelphia College of Pharmacy and Science, Pharmacy Management, Ja-35

Roche Laboratories, Advisory Board, Ja-12, 13; D-814, 815; Hospital Pharmacy Grant Winners, Ap-195, 196, 197; Ma-311, 312, ibc; Ju-367, 368, 369; Pharmacy Programs, S-547, 548; O-619, 620; N-703, 704; Research Grant Winners, Mr-134, 135; Roche Honors, F-106, 107

Sandoz Pharmaceuticals, Parlodol, F-94, 95; Ap-244, 245

Smith, Kline and French Laboratories, Hospital Image, Ma-280, 281; Ju-360, 361; O-586, 587; Selacryn, Ju-345, 346; JI-381, 382

United States Pharmacopoeial Convention, Two New Volumes, Ma-263

West Virginia University, Symposium on Microencapsulation, Ja-16

INDEX ABBREVIATIONS

ab: abstract

CTF: Current Therapeutic Findings

ctr: center insert

ed: editorial

ibc: inside back cover

ifc: inside front cover

obc: outside back cover

